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A significant challenge in the surgical resection of tumors is accurate identification of 
tumor margins. Current methods for margin detection are time-intensive and often result 
in incomplete tumor excision and recurrence of disease. The objective of this project was 
to develop a near-infrared narrowband imaging (NIR NBI) system to image tumor and its 
margins in real-time during surgery utilizing the contrast provided by gold nanoparticles 
(GNPs). NIR NBI images narrow wavelength bands to enhance contrast from plasmonic 
particles in a widefield, portable and non-contact device that is clinically compatible for 
real-time tumor margin demarcation. GNPs have recently gained significant traction as 
nanovectors for combined imaging and photothermal therapy of tumors. Delivered 
systemically, GNPs preferentially accumulate at the tumor site via the enhanced 
permeability and retention effect, and when irradiated with NIR light, produce sufficient 
heat to treat tumor tissue. The NIR NBI system consists of 1) two LED’s: green (530 nm) 
and NIR (780 nm) LED for illuminating the blood vessels and GNP, respectively, 2) a 
 vii 
filter wheel for wavelength selection, and 3) a CCD to collect reflected light from the 
sample. The NIR NBI system acquires and processes images at a rate of at least 6 frames 
per second. We have developed custom control software with a graphical user interface 
that handles both image acquisition and processing/display in real-time. We used mice 
with a subcutaneous tumor xenograft model that received intravenous administration and 
topical administration of gold nanoshells and gold nanorods. We determined the GNP’s 
distribution and accumulation pattern within tumors using NIR NBI.  
             Ex vivo NIR NBI of tumor xenografts accumulated with GNPs delivered 
systemically, demonstrated a highly heterogeneous distribution of GNP within the tumor 
with higher accumulation at the cortex. GNPs were observed in unique patterns 
surrounding the perivascular region. The GNPs clearly defined the tumor while 
surrounding normal tissue did not indicate the presence of particles. In addition, we 
present results from NBI of tumors that received topical delivery of conjugated GNPs. 
We determined that tumor labeling using topical delivery approach resulted in a more 
homogenous distribution of GNPs compared to the systemic delivery approach. Finally, 
we present results from the on-going in vivo tumor margin imaging studies using NIR 
NBI. Our results demonstrate the feasibility of NIR NBI in demarcating tumor margins 
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The identification and removal of residual tumors remains a challenge during 
intraoperative surgeries. An important cause of recurrence of cancer at the site is due to 
either incomplete surgical removal of the tumor or the presence of small residuals that are 
invisible to the surgeon. Several studies have identified resection margin status as an 
important prognostic factor; a margin-positive resection strongly predicts early 
recurrence and poor survival rates.1-7 For example, with pancreatic cancer, the 
challenging nature of resection along the retroperitoneal margin results in patients 
frequently undergoing incomplete resection.1-3, 8, 9 The challenge lies in accurately 
identifying tumor margins and successfully performing margin-negative resection during 
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surgery.10 Intraoperative identification of positive margins is also not routinely 
undertaken since the resection is usually carried out all the way to the retroperitoneal 
margin and additional tissue cannot be safely resected. Therefore, the identification of 
positive margin occurs only after the surgery when the pathology report is prepared. 
In the case of breast tumors, upon initial diagnosis, surgical removal followed by 
adjunctive therapy is the primary standard of care.11 The main purpose of breast 
conservation surgery is to remove the entire tumor and obtain clear margins (a zone 
devoid of tumor) around the cavity to decrease the chance of local tumor recurrence.  
However there are challenges identifying the residual tumor at the margin. Because of 
this, inadequate margins are found at the first operation in 20-55% of breast cancers 
removed by open lumpectomy.12-14 In addition, 75-90% of recurrences occur at the site of 
the original lumpectomy.15-17 It has been reported that the presence of clean surgical 
margins will reduce the 3-5 year rate of local recurrence.  Accordingly, techniques that 
result in improved initial surgical margins may have a significant impact on treatment 
costs, on disease progression and possibly on survival. 
Currently, for surgical removal of nonmelanoma skin cancers, the surgeon is 
required to take an excess margin of skin around the lesion to account for non-clinically 
relevant spread of the tumor.  This excess margin can result in a larger scar and greater 
cosmetic and functional deformity.  Non-melanoma skin cancers such as squamous cell 
carcinomas (SCCs) are typically removed using Mohs surgery. Mohs surgery involves 
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sequential removal of small layers of skin followed by examination under the microscope 
until the samples indicate no residual features or positive margins of SCC. Mohs surgery 
requires multiple excisions, with preparation of frozen sections and examination 
requiring 20 to 45 minutes per excision.18 In the case of large SCCs, several excisions 
may be required, and the total visit time may extend to several hours. Noninvasive 
imaging techniques for intraoperatively revealing the tumor margins and limiting the size 
of these surgical excisions would potentially spare patients from requiring expensive 
grafting and reconstruction procedures. Therefore, an intraoperative device is needed to 
provide information to guide precise tumor resection. 
 
1.2 Current imaging approaches 
While traditional imaging techniques have been used to identify the presence or location 
of tumors, current investigations often focus on the use of enhancing contrast agents for 
these traditional techniques or on entirely new methods.  Several imaging techniques are 
being investigated for use in the identification of tumor and its margins, including the use 
of systemically delivered agents to identify the tumor. Near-infrared absorbing 
nanocages, nanorods and nanoshells have been used in conjunction with optical 
coherence tomography and optoacoustic (photoacoustic) tomography to provide contrast. 
19-23 Some techniques rely upon the endogenous optical properties of tissue or 
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molecularly targeted agents.24 In general, these techniques focus on the identification of 
the cancer rather than precise delineation of its boundaries. 
Various techniques have been investigated to identify the margins of tumors as an 
aid to surgery.  Optical spectroscopy has been used to distinguish between normal brain 
tissues from tumor.  In one example, infiltrating tumor margins were distinguished from 
normal brain tissue with a sensitivity of 94% and a specificity of 93%.  This work relied 
on the optical properties of normal brain tissue compared to tumors, and the demonstrated 
level of sensitivity and sensitivity was lower than desired. 25-27 
Others have used conventional contrast agents for margin identification.  In one 
example, a paramagnetic iron oxide conjugated with a Cy5.5 near-infrared emitting dye 
was delivered intravenously, allowed to accumulate in the tumor.  Thereafter, the animals 
were sacrificed.  Blood was drained from the animals to reduce background (potentially 
reducing the background caused by blood in the dye-emission wavelength) and the 
tumors were imaged. The border of the tumor as indicated by a probe correlated well with 
other measurements of the tumor boundary.28 In other work, a near-infrared fluorescent 
small molecule specific for PSMA was used to provide image guidance for surgery.29 
Two challenges for this approach include the specificity and universality of the target 
(PSMA) and the background resulting from near-infrared fluorescence of 
blood/hemoglobin. 
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Quantum dots have also been investigated as a conventional contrast agent using 
the fluorescent emission properties of these particles.30 More recently, a targeted 
bioconjugate of the CY5.5 near-infrared fluorescing dye to a chlorotoxin with an affinity 
for MMP-2 was used for fluorescent imaging.  This group achieved positive results in 
animal models by detecting the fluorescent emissions from this conjugate.31 Further study 
may be required to determine any potential cross-reactivity in humans and the 
photobleaching of the near-infrared dye in the operating room light.  Additionally, 
fluorescent techniques may be hampered by the natural auto-fluorescence of human 
blood and tissue. 
 
1.3 Narrowband imaging 
Narrow band imaging (NBI) is a diagnostic technique clinically available today and used 
in several imaging applications to image morphology near the surface of tissue.  
Narrowband imaging is based on the phenomenon that the depth of light penetration in 
tissue depends on its wavelength, with longer wavelengths penetrating deeper into tissue.  
This technique illuminates tissue with a broadband source (e.g., white light) and uses 
narrowband filters in two or more wavelength bands in the visible spectra to capture 
reflected light.  The different wavelength bands are differentially absorbed or reflected by 
different tissue components, in particular hemoglobin, and allow the visualization of the 
vasculature near the surface. Again, this technique commonly relies upon the optical 
properties of endogenous tissue to distinguish healthy and abnormal tissue.  The common 
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wavelength bands utilized are in the blue and green area of the spectra, and some 
techniques also utilize a band in the red wavelength.  Relying on the absorption of each 
of these bands by hemoglobin, and the different transmission depths of these wavelengths 
into tissue, allows the visualization of surface or sub-surface vasculature or morphology. 
In recent years several research groups have used Narrow Band Imaging combined with 
endoscopy to differentiate normal and cancerous tissue in the Barrett’s esophagus, oral 
cavity.32,33 However, traditional narrowband imaging relies on differences in the 
endogenous optical properties of tissue, and is thereby limited in applications and 
specificity for many disease indications. 34-37 
 
1.4 Metal nanoparticles for imaging and therapy 
Metal nanoparticles have recently gained enormous interest as exogenous contrast agents 
in a variety of biomedical applications related to cancer detection and treatment. Metal 
nanoparticles include gold nanorods, gold nanoshells, carbon nanotubes, gold 
nanospheres, metal nanowires, semiconductor quantum dots and other nanoparticles 
produced from a variety of substances. As contrast agents, metal nanoparticles like gold 
nanoshells (GNSs) and gold nanorods (GNRs) have been used to detect and image 
individual cancer cells in vitro and in solid tumors in vivo. These gold nanoparticles 
(GNPs) can be designed to either absorb or scatter light in the visible and infrared regions 
of the electromagnetic spectrum.38 In particular, their plasmon resonance can be tuned in 
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the near infrared region where there is minimal absorption of light by biological 
chromophores and optimal penetration of light through tissue. 39, 40, 41 The biologically 
inert surface of GNPs also enables bioconjugation with cancer targeting ligands, thus 
facilitating selective binding to in vivo targets.42-44 In addition, gold nanoparticles possess 
strong photostability 45 and are thermally stable.46 The high thermal conductivity of gold 
makes them efficient for transferring heat to the surrounding. These unique optical, 
chemical and physical properties make them ideal candidates for molecular and cellular 
imaging, enhancing cancer detection and treatment. 
 
1.4.1 Gold nanoparticles as therapeutic agents 
Gold nanoparticles can absorb large amounts of energy due to their large optical 
absorption cross sections, when irradiated with a near-infrared (NIR) light and can 
effectively convert them to heat. In addition, GNPs injected systemically through the tail 
vein, passively extravasate from leaky tumor vasculatures and preferentially accumulate 
in tumors due to the enhanced permeability and retention (EPR) effect.47,11 This tumor 
specific accumulation and NIR activation can be exploited for thermal ablation of solid 
tumors using NIR illumination. Several in vitro studies have used NIR absorbing GNSs 
42, 48 and GNRs 49-54 for photothermal ablation of cells and tumors. Recently, in vivo 
models for photothermal ablation of tumors using GNSs and GNRs have been 
demonstrated by West et al. 11, 55 , El-Sayed et al.56 and Goodrich et al.. 57  
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1.4.2 Gold nanoparticles as contrast agents for imaging 
Because of optical tunability and high absorption and scattering cross sections, GNPs 
have been used as in vitro and in vivo contrast agents in several imaging applications. In 
addition to their potential applications as therapeutic agents, gold nanoparticles have 
gained popularity as scattering-based contrast agents in in vitro58,59 and in vivo 60 imaging 
strategies combined with therapy. Loo et al successfully bioconjugated GNSs with HER2 
antibodies to target human mammary adenocarcinoma cells in vitro.9 Targeted gold 
nanoshell bioconjugates demonstrated increased optical contrast for imaging human 
breast cancer cells using in vitro dark field microscopy.44 In addition, GNSs with high 
scattering cross sections have been used as effective contrast enhancement agents in vitro 
using optical coherence tomography.61 Wang et al. demonstrated enhanced contrast 
between blood vessels and the surrounding brain tissue due to gold nanoshell absorption 
using in vivo photoacoustic tomography (PAT).62 El-Sayed et al. have used anti-EGFR 
gold nanorods to detect and image two oral sqaumous carcinoma cell lines, HSC 313 and 
HOC 3.63, 64 The GNRs were found to specifically and homogenously bind to the surface 
of cancer cells with 600% greater affinity than non-malignant cells. Recently, researchers 
have taken advantage of the two-photon luminescence properties of GNPs. Some studies 
have used GNSs to image the 3D distribution in tumors 46 and image live breast cancer 
cells with immunotargeted GNSs using in vitro two-photon microscopy. 65  
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1.5 Narrow band imaging using gold nanoparticles 
Most imaging techniques utilize GNPs as contrast agents for enhanced visualization of 
targeted cancer cells at the microscopic level or as absorption agents to enhance contrast 
between blood vessels and surrounding tissue. However, in studies involving 
identification of tumor margins (e.g. breast tumor margin detection), one would require a 
wide-field, non-contact method to image and resect the positive margins and ablate in 
situations where resection is impossible. We use GNPs’ strong NIR absorption to 
demonstrate enhanced contrast between GNPs accumulated in the tumor and the 
surrounding vasculature and tissue using narrowband imaging. 
The primary objective of this research is to develop real-time, wide-field, non-
contact method to image the tumor and its margins using gold nanoparticles as contrast 
agents during surgery and perform photo thermal ablation of the residual tumor if 
necessary. Chapter 2 describes the design and development of a prototype NBI system. 
We validate the performance of the bench top NBI system on tissue-simulating phantoms 
and demonstrate the system’s capability to image tumors using gold nanoshells as 
contrast agents. Chapter 3 presents the optimized, clinical grade imaging system that can 
perform real-time imaging of samples at approximately 6 frames per second. We have 
demonstrated its real-time imaging capability using tissue-simulating phantoms. The 
optimized system is portable and noncontact, facilitating clinical compatibility 
particularly in a sterile operating field. In chapters 4 and 5, we perform studies using 
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tumor xenografts to determine the ideal parameters for tumor targeting such as 
nanoparticle type (gold nanoshells or gold nanorods), dosing strategy (single or multiple) 
and delivery method (systemic or topical). In chapter 6, we evaluate the feasibility of in 
vivo real-time imaging of breast and pancreatic tumors and tumor margins. We establish 
an animal model with minimal residual disease to mimic positive resection margins of 
pancreatic cancer. Finally, we demonstrate the feasibility of combined imaging and 









Near-infrared narrowband imaging 
 
2.1 Introduction 
In recent years several research groups have used NBI combined with endoscopy to 
differentiate normal and cancerous tissue in the oral cavity,32 esophagus33 and colon.66 
The technique involves illuminating light in narrow wavelength bands to enhance 
contrast of important endogenous tissue chromophores such as hemoglobin in blood 
vessels. By shining narrow bands of light of lower wavelengths, one can differentiate 
vascular patterns and the surrounding tissue surfaces with greater visual contrast. 
Visualization of increased vasculature (i.e. angiogenesis) is an important indicator of 
certain early cancer. Previous studies reported with NBI have used endogenous 
chromophores to distinguish normal from cancerous tissue.  
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 Here we report a new application of NIR NBI for imaging tumors using 
exogenous contrast agents. In particular, we report the use of GNSs, one of the class of 
near-infrared-absorbing materials available, as the exogenous contrast agent.  We used 
broadband light for illuminating the target and imaged select wavelength bands in the 
visible (VIS) and NIR regions to enhance visualization of hemoglobin and GNSs, 
respectively. We combined the absorption properties of hemoglobin and GNSs in the 
respective VIS and NIR wavelengths to specifically identify the tumor regions. We 
quantitatively determined the narrow wavelength bands providing high contrast for 
hemoglobin and GNSs using tissue simulating phantoms and found the optimum NBI 
wavelengths in the VIS and NIR to be 540 - 580 nm and 620 - 900 nm, respectively. We 
then performed ex vivo NBI of murine tumors accumulated with GNSs using two bands: 
580 nm for highlighting blood and 810 nm for highlighting GNSs.  
 
2.2 Materials and Methods 
2.2.1 NBI system 
We designed and developed a prototype NIR NBI system to image tumors and 
surrounding normal tissue in wide field. A schematic of the NBI system is shown in 
Figure 2.1. We used a quartz-tungsten-halogen lamp (100 W, Newport Stratford Inc., 
Stratford, CT) for white light illumination (400-1100 nm), a liquid crystal tunable filter 
(LCTF; Meadowlark Optics Inc., Frederick, CO) for wavelength selection and a cooled 
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12-bit CCD (CoolSnap, Photometrics, Tucson, AZ) to collect reflected light.  We used a 
bifurcated fiber optic cable (Dolan Jenner, Boxborough, MA) to focus the light directly 
onto the sample. The LCTF is a tunable band pass filter that has a full width at half 
maximum (FWHM) of ~5 nm tuned to operate in a wavelength range of 400-1100 nm. 
 
 





2.2.2 Gold/Silica Nanoshell Fabrication 
Nanoshells were obtained from Nanospectra Biosciences, Inc. (Houston, TX).  The GNSs 
fabrication is based on the method of Oldenburg38. Briefly, gold colloids, 1-3 nm in 
diameter, were grown over an aminated 120 ± 12 nm core of colloidal silica (Precision 
Colloids, LLC, Cartersville, GA).  Gold colloid and the particles were then further 
reacted with HAuCl4 in the presence of formaldehyde causing the gold surface to grow 
and coalesce, ultimately forming a complete shell.  The gold surface was then pegylated 
using thiolated polyethylene glycol (SH-PEG) (Laysan Bio, Huntsville, AL) to improve 
stability and blood circulation. GNSs formation and dispersion in solution were assessed 
using a UV-Vis spectrophotometer. Figure 2.2 illustrates the extinction spectrum of the 







Figure 2.2: UV-VIS extinction spectrum of GNSs. A concentration of 2.66 x 109 (100x dilution 
factor) particles/ml produced a peak OD of  ~1. 
 
 
A concentration of 2.66 x 109 (100x dilution factor) particles/ml produced a peak 
OD of ~1. The particles were designed to have a core size of 120 nm and a shell 
thickness of 15 nm resulting in an extinction peak between 800 and 810 nm. Based on the 
Mie theory calculations for these GNSs, the absorption cross-section was approximately 
25 % of the extinction cross-section (approximate scattering cross-section was 5.6 x 104 
nm2 and the absorption cross-section was 2 x 104 nm2). For passive targeting, a thiolated 
polyethylene glycol (SH-PEG) (Laysan Bio, Huntsville, AL) was added to the shell 
surface by combining 5 µM SH-PEG and GNSs in deionized water for 12 hr, followed by 
diafiltration to remove the excess SH-PEG. The GNSs were in 1L volume, at a 
concentration of approximately 4 x 109 particles/mL. This corresponds to a particle 
concentration of ~7 pM when 5 µM PEG-SH is added. We used 10% trehalose to 
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suspend GNSs for injection because GNSs exhibit greater long-term stability in trehalose 
compared to PBS. In addition, 10% trehalose is iso-osmotic with blood.  
 
2.2.3 Tissue Phantoms 
To determine the optimum wavelength bands and the GNSs detection limit, we used 
tissue-simulating phantoms of known optical properties. These phantoms were fabricated 
using polystyrene microspheres (diameter = 1.025 µm; Polysciences, Warrington, PA) to 
simulate scattering and hemoglobin (Sigma, St. Louis, MO) and GNSs (Nanospectra 
Biosciences Inc, Houston, TX) to simulate absorption. We used Mie theory to calculate 
the reduced scattering coefficient (µs’(λ)) and a spectrophotometer (DU 720, Beckman 
Coulter, Fullerton, CA) to measure the absorption spectra of hemoglobin and GNSs. 
  
 
Figure 2.3: Matrix of tissue simulating phantoms. (a) Composite NBI image (b) Standard color 




We prepared a set of six tissue simulating phantoms as shown in Figure 2.3. 
Phantom 1 (control phantom) contained polystyrene microspheres in de-ionized water 
and phantom 2 (hemoglobin phantom) contained polystyrene microspheres and 
hemoglobin ([Hb]=2 mg/ml; µa (λ=580 nm) = 0.36 mm-1). Phantoms 3-6 contained 
varying concentrations of GNSs (1X, 2X, 5X and 10X, where X refers to 1.14 x 109 
particles/ml) in polystyrene microsphere solutions. All phantoms contained the same 
density of polystyrene microspheres (µs’(λ0 = 630 nm) = 1 mm-1). The range of µa and µs’ 
for phantoms 3-6 at the peak extinction wavelength of GNSs (810 nm) was 0.02 – 0.21 
mm-1 and 0.82 – 1.38 mm-1, respectively. The µs’ of phantoms 3-6 represents scattering 
from both GNSs and polystyrene microspheres at 810 nm. GNSs concentration of 1X 
represents the physiological concentration shown to accumulate in tumors.67,68 We 
fabricated and imaged one additional GNSs phantom with a concentration of 0.5X; 
however, this phantom demonstrated minimal contrast from the control phantom.  
 
2.2.4 Animal Model 
We demonstrated NBI in tumor xenograft animal models of colorectal cancer. We used 
four to five week old Swiss nu/nu mice weighing 25-30 g each at four to five weeks old. 
Each animal was inoculated subcutaneously with human colorectal cancer cells 
(HCT116, ATCC #CCL-247). The test group (n = 5) received 4.7 µl/g of GNSs solution 
standardized to an optical density of 97 at 811 nm (2.66 x 1011 particles/ml) injected 
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intravenously via the tail vein. The control mouse received 4.6 µl/g of the trehalose 
vehicle. Previous studies show that the maximum accumulation of GNSs in tumors is 24 
hours post injection.67 Therefore, we sacrificed the mice after 24 hr following GNSs 
injection and excised the bulk tissue containing the tumor from the mice to expose the 
subcutaneous side of the tumor for imaging. We performed imaging within 10-15 
minutes of tumor excision. Excess blood from the tumor extraction was minimal and did 
not obscure the field of view. 
 
2.3 Results 
2.3.1 Optimum imaging wavelengths 
We determined the optimum imaging wavelengths for NBI using tissue-simulating 
phantoms. Optimum imaging wavelengths are the wavelengths providing maximum 
contrast between hemoglobin and GNSs in the tumor. We collected hyperspectral images 
of the set of tissue-simulating phantoms from the visible to NIR regions (500 – 900 nm) 
to determine the optimum imaging wavelengths. We constructed an image cube by 
collecting intensity images of the phantoms at 22 different wavelengths by tuning the 
LCTF.  
In our study, the contrast was evaluated quantitatively and defined as the 
luminance ratio (ratio of the difference between sample intensity and background 
intensity to background intensity) according to Weber’s law.69 In the contrast calculation, 
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the background intensity is that of the control phantom and the sample intensity 
corresponds to hemoglobin and GNSs phantoms. We selected a small region of interest 
(100 x 100 pixels) from the imaged sample for each wavelength to calculate contrast for 
the hemoglobin phantom and one GNSs phantom (10X).  
 
 
Figure 2.4: Contrast of hemoglobin phantom and GNS phantom in VIS-NIR region. The shaded 
areas represent the NBI wavelengths bands. (VIS image at 580 nm and NIR image at 810 nm) 
 
 
A contrast plot for hemoglobin phantom and the GNS phantom in the 
wavelengths ranging from 500 – 900 nm is shown in Figure 2.4. The hemoglobin 
phantom contrast peaks at 540 nm and 580 nm, corresponding to the Q-bands of oxy-
hemoglobin. The hemoglobin phantom contrast is minimal beyond 620 nm. The GNS 
phantom’s contrast remains high throughout, with the peak at approximately 620 nm. The 
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contrast peak of the GNS phantom appears to have a blue shift relative to the ~800 nm 
peak observed in the extinction spectrum of Figure 2.2. Therefore, the optimum 
wavelength bands for enhancing contrast of hemoglobin and GNSs are 540- 580 nm and 
620 – 900 nm, respectively. The subsequent NBI images use two bands: 1) VIS image: 
580 nm for highlighting blood and 2) NIR image: 810 nm for highlighting GNSs. The 
shaded areas seen in Figure 2.4 represent the NBI wavelengths bands. 
 
2.3.2 NBI of tissue phantoms 
We collected narrow band images of tissue simulating phantoms to demonstrate the 
concept of NBI using the wavelength bands identified in the previous section. Using the 
standard RGB format, we assigned the red channel to the VIS image and the green 
channel to the NIR image. The composite NBI image was constructed by overlaying the 
two images as shown in Figure 2.5a. The composite narrow band image visually provides 
enhanced contrast of the hemoglobin phantom and the GNS phantom as compared to the 
standard color image shown in Figure 2.5b. To further demonstrate the NBI image 
characteristics, we selected small areas from the tissue phantom matrix of VIS and NIR 





Figure 2.5: NBI images of small areas from tissue phantom matrix to demonstrate NBI image 
characteristics. 
 
We observe high visual contrast of the hemoglobin phantom in the VIS grayscale 
image resulting in a bright red NBI composite image for the hemoglobin phantom. The 
control phantom has relatively little contrast in either VIS or NIR band resulting in a 
bright yellow composite NBI image. The GNS phantoms exhibit increasing contrast with 
higher GNS concentration resulting in an increasingly green NBI image as GNS 
concentration increased. These tissue phantoms provide an estimate of the detectable 




Figure 2.6: Contrast provided by GNS phantoms to estimate detectable concentration in tissue. 
The error bars represent the ratio of standard deviation to mean signal intensity for different GNS 
concentrations. The black line represents the background noise. 
 
The physiological concentration of GNSs in tumor (1X) provides at least 20 % 
contrast from the background noise (3 %) indicated by the line in Figure 2.6. The 
background noise is the ratio of standard deviation to mean signal intensity of the control 
phantom. However, we observe that the concentration of GNSs providing more than 40 
% contrast is between 5X and 10X.   
 
2.3.3 NBI of murine tumors 
We performed ex-vivo imaging of Swiss nu/nu mice inoculated with human colon cancer 
cells. Narrow band images of both the control mouse and GNSs injected mice were 
collected. A small portion from the tumor was selected to illustrate the micro-distribution 
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of hemoglobin and GNSs using the NBI technique. In the ex-vivo NBI images, the blood 
vessels are clearly visible in the VIS image as seen in Figures 2.7a and d. 
 
 
Figure 2.7: Upper panel: Narrow band images of human colon tumor. (a) Grayscale VIS image 
(580 nm) (b) Grayscale NIR image (810 nm) (c) Composite NBI image. The black arrows 
indicate GNSs in tumor. Lower panel: Narrow band images of control tumor (injected with 
trehalose). (a) Grayscale VIS image (580 nm) (b) Grayscale NIR image (810 nm) (c) Composite 
NBI image. 
 
In the NIR image of the GNSs injected mouse, the GNSs accumulated tumor 
regions are clearly visible as dark areas as seen in Figure 2.7b. The control tumor 
indicates only the blood vessels as seen in Figure 2.7d. The advantage of NBI is clearly 
demonstrated in the composite NBI images. The composite NBI images of three other 
tumors accumulated with GNSs are shown in Figure 2.8 demonstrating the various 
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accumulation patterns seen among the tumors. The fifth mouse did not show significant 
particle accumulation by NBI. The black arrows in the images indicate focal regions of 
higher concentrations of the GNSs. 
 
     
Figure 2.8: Composite NBI images of human colon tumors illustrating heterogeneous distribution 
of GNSs. The black arrows indicate GNSs in tumor. 
 
2.4 Discussion 
We have demonstrated NIR NBI for imaging GNSs systemically delivered to tumors. 
NBI uses a narrow band of wavelengths matched to the chromophores of interest to 
highlight contrast between tissue constituents and exogenous contrast agents. Although 
we have used GNSs as the NIR absorbing particle to provide contrast between 
hemoglobin and GNSs in tumor, one could use other nanoparticles such as nanorods63 
that can be tuned to absorb in the NIR or organic dyes such as Indocyanine Green.70 In 
tissue phantoms containing only hemoglobin, we observe peak contrast between 540 and 
580 nm (Figure 3) consistent with the absorption peaks of hemoglobin. In tissue 
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phantoms containing GNSs and no hemoglobin, we observe high contrast throughout the 
500-900 nm range with a peak at approximately 620 nm. The GNSs with a core diameter 
of 120 nm and a shell thickness of 15 nm are anticipated to have an absorption peak 
around 800 nm58. While the peak contrast in tissue phantoms is blue shifted from that of 
pure GNSs in solution, the contrast remains high above 600 nm. Therefore, in order to 
avoid hemoglobin absorption contrast and maintain high contrast from GNSs, one should 
choose a band greater than ~620 nm. Based on this analysis, hemoglobin and GNSs 
contrast can be enhanced by selecting bands between 540 – 580 nm and 620 – 850 nm, 
respectively. In addition, as we move from the visible to NIR wavelengths, the scattering 
from tissue decreases, allowing for imaging of GNSs at greater depths. Therefore, we 
chose to image tissue phantoms and murine tumors in two bands: VIS image (580 nm) 
and NIR image (810 nm).   
The tissue phantom images obtained using the optimum imaging wavelengths 
demonstrate the concept of NBI (Figure 2.3a). Figure 2.5 depicts the intensity variations 
due to varying concentrations of GNSs. In the composite NBI image, we observe the 
yellow color (control) to correspond to the tissue background. The hemoglobin phantom 
is assigned a red channel to depict the color of blood in tissue. We observe that as the 
concentration of GNSs increase, the yellow intensity decreases due to increase in 
absorption, which is shown by the increasing intensity of green color. 
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Figures 2.7 and 2.8 demonstrate magnified ex-vivo images of mice inoculated 
with human colon cancer cells and injected with GNSs. Although we did not quantify the 
imaging depth, the imaging depth should be related to tissue optical properties. Based on 
the mean free path (mfp), the imaging depth in the NIR is approximately 1 mm (the 
estimated mfp for rat skin is ~760 µm at 810 nm) 71. We observe GNSs labeled in green 
are clearly distinguishable from blood vessels labeled in red. The black arrows highlight 
regions indicating the presence of GNSs. The effects of uneven illumination resulted in 
the greenish background present in some of the composite NBI tumor images (eg. Figure 
2.7c). In these images, the background should ideally be uniformly yellow in color. The 
punctate areas in these composite NBI images are GNSs. Improvement in the target 
illumination will eliminate shadows and hot spots in the collected images.  
Although we assume that the average concentration of GNSs accumulated in the 
tumor is 1X, GNSs tend to accumulate in small focal volumes of high concentrations in 
tumors as seen in Figures 2.7c and 2.8. The contrast seen in these images can be related 
to the tissue simulating phantoms in Figure 2.5, suggesting the focal areas of high GNSs 
contrast have concentrations much higher than 1X. In addition, the heterogeneous 
distribution of GNSs suggests that the previously measured average 1X concentration for 
the whole tumor is actually located in focal regions. Although our images only show 
superficial tissue layers, recent studies suggest that GNSs accumulate in the tumor 
cortex,72 and therefore, this focal heterogeneous distribution is volumetric, suggesting 
these “hot spots” may have concentrations many times the volumetric average values 
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previously reported. Using NBI, we observed GNSs accumulation in four out of the five 
mice injected with GNSs represented in Figures 2.7c and 2.8. We believe that the tumor 
identified with no accumulated GNSs possibly had very minimal particles accumulated at 
the tumor site due to problems with particle delivery. This may be due to inadequate 
delivery of GNSs to the tail vein during injection.  
 We observed a heterogeneous accumulation of GNSs in the GNSs injected mice. 
Previous studies have demonstrated this heterogeneous nature of GNSs distribution in 
tumor. Li et al. imaged the passive accumulation of GNSs in murine colon tumors grown 
in BALB/c mice using photoacoustic microscopy and found GNSs to accumulate 
heterogeneously in the tumor, characterized by high concentrations in the tumor cortex 
and very low concentrations in the tumor core.72 Park et al. also reported heterogeneous 
nature of GNSs accumulation in tumor and found that GNSs were located in close 
proximity to blood vessels using two-photon luminescence technique.46 In-vivo thermal 
therapy of GNSs accumulated tumor performed by Hirsch et al. have reported that the 
temperature distribution from NIR irradiation is non-uniform due to the diffuse 
distribution of GNSs over the tumor.55 Recently, Diagaradjane et al. reported high 
concentrations of GNSs within the perivascular region of tumors accounting for the high 
temperature increase in this region that resulted in vascular disruption after radiation 
therapy.73 Further macroscopic NBI imaging could be performed to better understand the 
cause of the varying pattern of GNSs accumulation and GNSs accumulation specificity 
within the tumor.  
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The composite narrow band images demonstrate the potential use of NIR NBI 
technique for identifying GNSs accumulations within tissue and suggest several 
applications to this technique. Given that these particles preferentially accumulate at the 
tumor site, one may potentially use NIR NBI clinically to identify tumors and their 
margins during surgery pre- and post-resection. Given the high photothermal efficiency 
of GNSs, NBI may be used as a combined imaging and photothermal therapy platform 
for both identifying and ablating tumors, their margins, and residual disease after 
resection. The narrow band images could potentially guide in precise photothermal 
therapy without causing damage to surrounding normal tissue. For basic science 
applications, the narrow band images of tumor accumulated with GNSs will aid in 
understanding the nature of particle distribution within the tumor. For example, as metal 
nanoparticles are actively being studied for photothermal treatment of solid tumors, one 
may wish to use NBI to image particle distributions within tumors of a test model (e.g. 
mouse tumor xenograft). As new applications for the use of NIR absorbing nanoparticles 
are developed, NBI can serve as a tool for distinguishing particle locations within tissue.  
The proposed optical imaging technique is minimally invasive. The NBI system 
has simple instrumentation, is easily portable and is “non-contact” which facilitates 
clinical compatibility particularly in a sterile operating field. While we have 
demonstrated snapshot imaging in the current study, the simplicity of NBI 
instrumentation would allow for video rate imaging. The composite NBI image obtained 
containing the enhanced visualization of blood vessels and GNSs will help in 
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understanding the extent of angiogenesis at a macroscopic level. The feasibility of NBI 












Optimized near-infrared narrow-band imaging system 
 
3.1 Introduction 
In Chapter 2, we presented a bench-top prototype of the NBI system. We demonstrated 
the feasibility of the technique on tissue-simulating phantoms and a colon cancer cell 
line. The instrument acquired snapshot images of the tumor and worked well for 
measurements on ex vivo tissue samples in the lab. However, clinical translation for the 
purpose of surgical guidance requires a nearly continuous feed or video-rate imaging of 
the tumor. Clinical translation also dictates an easily portable and compact system that 
can be easily moved between rooms. In this chapter, we discuss our efforts towards 
optimizing the size of the system as well acquiring real-time images of tissue-simulating 
phantoms. 
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3.2 Methods and Results 
3.2.1 Second-generation NBI system - hardware 
 
The prototype NIR NBI system described in Chapter 2 used a liquid crystal tunable filter 
(LCTF) for selecting wavelength bands. Although this is an efficient method of tuning 
wavelengths compared to individual filters, we deemed it unnecessary from both a 
technical as well economic standpoint. The LCTF can select wavelengths in 5 nm 
increments from 400-1100 nm and has a switching speed of approximately 100 ms. In 
addition, it is bulky and quite expensive. Our phantom experiments showed that we only 
needed two wavelength bands – one in the visible wavelength band and one in the NIR. 
We also need to switch faster than 100 ms to be capable of video-rate imaging (~30 
images/s). Therefore, we replaced the LCTF with a filter wheel for multiple wavelength 
selection. The filter wheel can hold up to 5 filters and with the addition of a stable AC 
motor is capable of switching between filters every 30 ms. We used two band pass filters 
(Semrock, Inc., Rochester, NY): 1) a VIS filter centered at 536 nm with a bandwidth of 
40 nm and b) a NIR filter centered at 536 nm with a bandwidth of 41 nm to image the 
blood vessels and GNRs, respectively. We incorporated an AC motor (DigiKey Corp., 
MN) to control the filter wheel rotation. The collection of images was timed to a trigger 
from an optical interrupt (DigiKey Corp., MN) that triggers at the respective filter 
positions.  We used an achromatic lens (Edmund Optics, Barrington, NJ) instead of the 
manual focusing lens. We replaced the Coolsnap Photometrics CCD with a smaller and 
 32 
inexpensive 12-bit CCD (Basler Pilot, Graftek Imaging, Austin, TX) without 
compromising any significant camera features.  
Another change that could significantly impact the acquisition time is the choice 
of light source. We replaced the tungsten halogen lamp with a light emitting diode (LED) 
illumination system. The illumination system consists of two LED’s (Tholabs Inc., 
Newton, NJ):  green (530 nm) and NIR (780 nm) for illuminating the blood vessels and 
nanoparticles, respectively. Condenser lenses on both the LED’s collimate the incident 
light on the sample.  There are separate driver circuits to control the light output from 
each LED. The integrated real-time NIR NBI system is shown in Figure 3.1. 
 
 




3.2.2 Second-generation NBI system - software 
 
We developed custom control software in the LabVIEW® (National Instruments, Austin, 
TX) graphical programming environment to handle both image acquisition and 
processing/display. The image acquisition sequentially acquires sets of two images, one 
visible and one NIR at a camera exposure time of 10 ms. For real time imaging, the 
images are converted to 8 bit, binned by a factor of 4 resulting in an image size of 512 x 
625 pixels. The custom control software constructs the composite narrowband image for 
display. This includes inverting and assigning the visible images to the red channel and 
NIR images to the green channel, respectively. Additionally, we developed a graphical 
user interface to display the images and provide controls to dynamically adjust the image 
features such as brightness and contrast of each channel. Figure 3.2 shows the GUI (front 




Figure 3.2:  Snapshot of LABVIEW front panel that displays real-time image acquisition and 
processing at approximately 6 fps. 
 
The second-generation system is capable of acquiring images at 6 frames per second. 
Although this is not quite video-rate yet, it is still a significant improvement over the first 
generation system. 
 
3.2.3 Real-time imaging of tissue simulating phantom 
We used a polydimethylsiloxane (PDMS) phantom to demonstrate the real-time image 
acquisition and processing capability of the NIR NBI system. The phantom consisted of 
red food dye to simulate absorption in the VIS wavelength and varying concentrations of 
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gold nanoshells to simulate absorption in the NIR wavelengths. The red square shaped 
phantom corresponds to the red food dye to simulate absorption in the VIS. The different 
shapes of the GNS phantoms correspond to different concentrations as indicated in Fig. 
3.3. The figure shows excellent contrast between the different concentrations of GNSs. 
We also rotated the petri dish containing the phantoms and continuously acquired images. 
The image acquisition and processing was fast enough to keep up with the manual 
rotation and maintain the correct colors for the VIS and NIR phantoms. 
 
 
Figure 3.3: PDMS phantom used in the study. The red phantom contains a red food coloring dye 
that absorbs in the visible range. The other phantoms correspond to varying concentrations of 
GNSs.  X corresponds to 1.10 x 109 GNSs/ml. 
 
3.2.4 Determination of imaging and depth sensitivity: 
We determined the depth sensitivity of the NIR NBI system using a 3D tissue-simulating 
phantom. We fabricated tissue-mimicking phantoms using TiO2 mixed with PDMS (1.8 
mg TiO2/g PDMS) to simulate tissue scattering. After continuous stirring to ensure a 
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homogeneous mixture, the PDMS mixture was poured into a well containing openings in 
the walls at different depths. We inserted open capillary tubes (diameter = 400 µm) into 
the PDMS mixture through the openings to simulate blood vessels located at different 
depths. We injected gold nanorod concentrations ranging from ~ 8.5 x 1010 – 2.5 x 1013 
particles/mL into these channels and acquired images using the NIR NBI system. Figures 









(a)       (b) 
 
Figure 3.4: (a) Color image of a phantom containing gold nanorods that are injected in various 
channels (b) Grayscale NIR NBI image of a phantom obtained at 769 nm. The channels were 
injected with gold nanorods of concentration 5.16 x 1012 particles/ml. 
 
We calculated the contrast as a function of depth for the different GNR 
concentrations in the NIR wavelengths. The dilutions used in the study and their 
corresponding concentration values are shown in Table 3.1. The contrast was evaluated 
quantitatively and defined as the luminance ratio (i.e., the ratio of the difference between 
sample intensity and background intensity to the background intensity) according to 
 37 
Weber’s law. In the contrast calculation, the background intensity is from the TiO2 
substrate and the sample intensity corresponds to GNRs in each channel.  
Table 3.1. Gold nanorod dilutions used in the study with the corresponding concentration values. 
Dilution factors GNR concentration (particles/ml) 
Stock solution 2.58 X 1013 
15X 1.72 X 1012 
30X 8.6 X 1011 
80X 3.22 X 1011 
150X 1.72 X 1011 
300X 8.6 X 1010 
  
The experiment demonstrated a decrease in contrast values for higher depths as 
shown in Figure 3.5a. We observed that the contrast from different dilutions was minimal 
beyond 2 – 2.4 mm. The attenuation of the signal from the surface of the phantom to 
deeper channels was attributable to scattering from the substrate. Additionally, we 
observed the contrast from 150X dilution to be similar to the background noise 
suggesting that GNR concentrations below 1.72 X 1011 particles/mL in the channels were 
difficult to detect (Figure 3.5b) by the NIR NBI system and GNRs could not be 






   (a)      (b)  
Figure 3.5. (a) Contrast provided by GNRs at different depths for varying gold nanorod dilutions. 
(b) Contrast provided by GNRs on the top channel (approximately on the phantom surface) for 
different gold nanorod dilutions. The error bars represent the standard deviation of contrast values 
for each dilution. The black line represents the background noise (0.02). 
 
3.3 Discussion 
This chapter presents a second-generation instrument that is capable of real-time imaging 
in the clinic. The modified NIR NBI system used in this study provides benefits in terms 
of ease of operation and uniform illumination. Incorporating a powerful LED 
illumination system and a faster AC motor to control the filter wheel helped increase the 
acquisition rate to 6 fps. The NIR NBI was shown to provide excellent contrast up to a 
depth of at least 2 mm. As discussed in Chapter 2, the NIR NBI system could potentially 
provide a valuable method for surgical guidance during breast conserving surgery, 
pancreatic tumor resection and Mohs surgery for melanoma and non-melanoma skin 









Optimal parameters for efficient nanoparticle delivery 
 
4.1 Motivation 
The design as well as physical and chemical properties of nanoparticles is key to 
achieving effective tumor targeting and consequently improving cancer diagnosis and 
treatment. The results presented in Chapter 2 showed a heterogeneous accumulation of 
gold nanoshells in small focal regions. Given the long-term goal of using nanoparticles 
for ablative therapy, understanding particle accumulation and distribution profiles 
assumes significance for determining optimal therapeutic parameters. In this chapter, we 
discuss the studies performed to determine the effect of particle type, size and dosing 




In vivo tumor targeting using nanoparticles has primarily been achieved using EPR.47 The 
tumors’ inherent leaky vasculature and ineffective lymph system, enables systemically 
circulating nanoparticles to extravasate and accumulate in tumors due to the EPR effect.57 
Recent efforts have focused on active targeting, that exploits the over-expression of 
surface receptors on cancer cells by providing targeting ligands that can engage these 
receptors.42-44 Choi et al. demonstrated that targeted nanoparticles could provide greater 
intracellular delivery of therapeutic agents to the cancer cells within solid tumors than 
their nontargeted analogs.74 Although there is continuous effort to identify suitable 
targeting moieties and ideal design parameters for active and passive targeting, 
respectively, little is known about the effect of particle type and nanoparticle dosing 
strategies on tumor targeting and accumulation capacity.  
Multiple dosing is most commonly used in chemotherapy, photodynamic and 
radiation therapy for improved cancer treatment efficacies.75-77 Recently, a group 
demonstrated that a multiple dose of a photosensitizing agent MV6401 effectively 
induced tumor growth delay in mammary adenocarcinoma cells compared to a single 
dose.78 In the present study, we investigate the effect of a multiple dosing strategy using 
pegylated gold nanoparticles to increase the in vivo tumor targeting competence. 
As described previously in Chapter 1, pegylated GNPs are ideal for in vivo use as 
they are stable, non-toxic and possess unique optical and thermal properties that make 
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them effective contrast and photo-thermal agents.53, 55 The poly ethylene glycol (PEG) 
coating on the gold nanopaticles’ surface enables them to circulate longer and reduce 
non-specific uptake by the reticuloendothelial system (RES).42 The RES, one of the 
body’s filtration and defense mechanism, functions to remove foreign particles, irregular 
red and white blood cells as well as opsonized particles.79 The liver and spleen that 
belong to the RES system are mainly responsible for the removal of different sized 
particles and hence these organs absorb a large percentage of systemically administered 
nanoparticles.80 Most of the biodistribution studies have shown that approximately 50 - 
60 % ID/g of nanoparticles are taken up by the liver and spleen, respectively.81 
 Particles of sizes ranging from 10 nm to 15 µm have different biodistribution and 
pharmacokinetic parameters.82 Experiments from animal models suggest that sub -150 
nm, neutral or slightly negatively charged entities can move through tumor tissue.83 
Recent data show that systemically delivered nanoparticles in the 50–100 nm size range 
that carry a very slight positive charge can penetrate throughout large tumors.84 
Therefore, nanoparticles in the 10 - 150 nm size range and with a neutral charge should 
have access to tumors when dosed into the circulatory system.85 Perrault et al. have 
examined the particle size-dependent permeation of the tumor mass for 20 -100 nm size 
range, and revealed a difference in behavior for different sizes and demonstrated that 
particle design has tremendous consequences on tumor targeting behavior.86  
  In this chapter, we will investigate the effect of multiple dosing of GNPs and 
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nanoparticle type to improve tumor-targeting efficiency. We utilized large pegylated 
GNSs and small pegylated GNRs and compared the effect of size and shape of these 
particles on the tumor targeting efficiency. In addition, we compared the effect of single 
and multiple doses of GNRs and GNSs on in vivo tumor targeting. We will finally 
perform imaging of the tumors accumulated with both particle types for single and 
multiple dosing using the modifed NBI to evaluate the contrast enhancement in the 
images as a function of particle dosing.  
 
4.3 Materials and Methods 
4.3.1 Synthesis of pegylated gold nanoshells and nanorods 
The nanoshells used in this study were fabricated as described in detail in Chapter 2. 
Nanorods were synthesized using the method developed by Jana et al.87 Briefly, gold 
seed particles were prepared by adding 250 µL of 10 mM HAuCl4 · 3H2O to 7.5 mL of 
100 mM CTAB with brief, gentle mixing. Freshly prepared 600 µL of ice-cold 10 mM 
NaBH4 solution was added and the solution was mixed for 2 minutes. The nanorod 
growth solution was prepared by adding 40 mL of 100 mM CTAB, 1.7 mL of 10 mM 
HAuCl4·3H2O, and 250 µL of 10 mM AgNO3 followed by 270 µL of 100 mM ascorbic 
acid. To initiate nanorod growth, 840 µL of the seed solution was added to the growth 
solution, mixed gently, and left still for 40 minutes. Excess reactants were removed by 
centrifugation and re-suspension in de-ionized (DI) water. For in vivo applications, the 
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GNRs were PEGylated by the addition of 1 mM thiol-terminated methoxypolyethylene 
glycol (mPEG-SH) (Laysan Bio, Arab, AL) and the solution was stirred overnight. The 
final PEGylated rod solution was cleaned by diafiltration of the solution into DI water. 
The synthesized GNRs had an aspect ratio of approximately 3.42 (GNR size: 24 x 7 nm). 
Both GNSs and GNRs were suspended in 10% trehalose because the particles exhibit 
greater long-term stability in trehalose compared to PBS. In addition, 10% trehalose is 
iso-osmotic with blood. Figure 4.1 illustrates the normalized extinction spectra of GNSs 
and GNRs used in this study. 
 
 
Figure 4.1: UV-VIS extinction spectra of GNSs and GNRs. 
 
4.3.2 Cell culture and tumor inoculation in mice 
A431 cells (CRL- 1555, ATCC, human epithelial carcinoma cell line) were grown in 
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Dulbecco's Modified Eagle's medium (30-2002, ATCC) with 10 % fetal bovine serum 
(30-2020, ATCC) at 37 °C under 5 % CO2. When culture reached 90 % confluency, the 
cells were detached from the flask by 0.25 % trypsin-EDTA (30-2101, ATCC), 
centrifuged, and resuspended in sterile phosphate-buffered saline (PBS).  4 to 6 week old 
nude mice (Swiss nu/nu) were inoculated with the A431 cells. Approximately 4 x 106 
cells/50 µl were subcutaneously injected in the right thigh of the mice. When tumors 
attained a size of ~ 8-10 mm in diameter, we performed intravenous delivery of 
nanoparticles.  
 
4.3.3 Single and multiple dosing 
GNSs and GNRs solutions were intravenously injected via the mouse-tail vein for single 
and multiple doses at 24-hour intervals. We systemically injected nanoparticles at 24 
hour intervals since this time point has shown bulk nanoparticle clearance from blood 
allowing maximum particle accumulation in tumors.67, 88 We distributed 38 mice into 6 
different groups. Table 1 shows the animal use for a range of doses and both particle 
types. Groups 1 and 2 animals received 7 µl/g of a single GNP dose (GNSs: 2.74 x 108  
particles/ µl and GNRs: 2.005 x 1011  particles/ µl, optical density = 100) and were 
sacrificed after 24 hours followed by tumor and organ extraction for analysis. Groups (3 
and 4) and Groups (5 and 6) received multiple GNP doses once per day for three days 
and five days consecutively at 24-hour intervals, respectively. Following the three and 
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five GNP doses, animals were sacrificed and the organs were extracted for analysis on 
the fourth and sixth day, respectively. Our control group consisted of three mice that 
received intravenous administration of trehalose. 
 
Table 4.1: Number of animals utilized in each dosing group for GNSs and GNR injections. 
 
Particle type Doses administered 
 Single Three Five 
GNS Group 1 (n=7) Group 3 (n=6) Group 5 (n=6) 
GNR Group 2 (n=7) Group 4 (n=6) Group 6 (n=6) 
 
4.3.4 Neutron Activation Analysis (NAA) 
We performed Neutron Activation Analysis (NAA) to quantify the amount of gold 
present in the extracted tumors and livers from the six mice groups. NAA is the gold 
standard method for trace gold quantification in biological samples, with sensitivities 
down to 70 pg.67 NAA was performed in the Nuclear Engineering Teaching Laboratory 
(NETL) at The University of Texas at Austin. Extracted tissues were weighed and placed 
inside the NAA vials. Following mass measurements, the vial containing tissue samples 
were placed in a desiccator and dehydrated for a week. Once desiccated, the vial lids 
were closed, and samples were sent to NETL for irradiation. From the amount of gold 
(mass of gold present in the samples) reported through NAA, and theoretical values for 
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the mass of a single GNP, we calculated the number densities of GNSs and GNRs in the 
tumors and livers for all animal groups. The theoretically estimated mass of a single GNS 
(120 nm diameter core with 15 nm shell) and GNR (24 x 7 nm) were 1.33 x 10-8 µg and 
1.61 x 10-11 µg (ρgold = 19.32 g/cm3). Additionally, to compare the percent-injected dose 
for GNS and GNR, the gold mass present in the injected samples (standards) were 
determined using NAA. Standards of GNSs and GNRs were prepared in NAA vials 
similar to the tissue preparation and were sent to NETL for irradiation. Based on the 
number of particles injected (reported from NAA of standards) and the number of 
particles accumulated in the tumors and livers (reported from NAA of tissue samples) for 




We performed histopathological analysis to determine if there was acute toxicity in 
tumors and in the RES organs (liver and spleen) for the mice groups that received the 
highest GNP dose (five doses). Liver, spleen and tumor from groups 5 and 6 was 
examined by a pathologist at MD Anderson Cancer Center. The tissues from groups 1 
and 2 (single dose) and the control group (trehalose injected) were also examined for 






4.4.1 NAA – Single and multiple dosing of GNSs and GNRs  
Figure 4.2 shows the accumulation of GNSs and GNRs in the tumor and liver for single, 
three and five doses based on NAA. These results show that three successive doses of 
GNPs lead to a nearly proportional accumulation in the tumors.  
 
 
Figure 4.2: (a and b) Number density of GNSs/g of tissue for different doses (single, three and 
five) in tumor and liver, respectively. (c and d) Number density of GNRs/g of tissue for different 
doses in tumor and liver, respectively. Error bars represent standard error.  
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Specifically, three consecutive doses rendered approximately 2 and 2.45 times 
increase in particle accumulation with GNSs and GNRs, respectively (Figures 4.2a and 
c). However, particle accumulation in tumors receiving five consecutive doses of GNPs 
via the tail vein was less than expected. We observed only a 3-time increase with GNSs 
and 1.6-time increase with GNRs in tumors for five doses. Note that the fold increase we 
refer to here is relative to a single dose. In summary, we observed an increase in the 
number densities of GNSs and GNRs in the tumor for higher doses (three and five doses) 
compared to a single dose (Figures 4.2a and c). Specifically, one versus three doses and 
one versus five doses were statistically significant for both GNSs and GNRs. In the liver, 
which serves as a control, we observed a concomitant increase in number densities for 
GNSs with increase in doses: 3 and 4.6 times increase for three and five doses, 
respectively (Figure 4.2b). However, for livers accumulated with GNRs, we observed an 
increase in number densities from single to three doses (3 times increase) and a decrease 
from third to the fifth dose. However, this decrease/change was statistically insignificant. 
We also observed a similar, statistically insignificant decrease in the GNR tumor group. 
 
4.4.2 NAA - Effect of particle type on tumor uptake  
We observed a significant difference in tumor uptake of GNSs and GNRs for a single 
nanoparticle dose. Figure 4.3 illustrates the fraction of GNSs and GNRs accumulated in 
tumor and liver for a known injected particle dose. 
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Figure 4.3: Percent injected dose per gram of tissue (%ID/ g of tissue) for GNRs and GNSs in (a) 
tumor and (b) liver after 24 hrs. post intravenous injection. GNRs accumulated approximately 
twelve times higher than GNSs in the tumor. Error bars represent standard error. 
 
In the tumor, the smaller pegylated GNRs showed approximately 12 times higher 
accumulation (1.35 ± 0.29 %ID/g tissue) compared to the larger pegylated GNSs (0.118 ± 
0.027 %ID/g tissue) after 24 hours. Similarly, we observed 15 and 6 times increase in 
percent accumulation for GNRs compared to GNSs at 72 and 120-hour time points, 
respectively (data not shown for 72 and 120 hour).  However, in the liver, there was no 
statistical difference in the percent accumulation of GNSs and GNRs (GNSs: 42 ± 2.11 




4.4.4 Narrowband imaging - single and multiple dosing of GNSs and GNRs 
 
We used NBI to image the nanoparticle distribution and accumulation pattern in A431 
tumors. In addition to the heterogeneity of nanoparticle accumulation in tumor, we 




       
Figure 4.4. Narrow band images of GNR accumulated tumor. Nanorods are in close proximity to 
blood vessels. (a) VIS grayscale NBI image (b) NIR grayscale NBI image (c) VIS image inverted 
and assigned to red channel (d) NIR image inverted and assigned to green channel (e) composite 
NBi image combined using images c and d.  
 
Figure 4.5 presents a comparison of NBI images acquired from tumors that 
received one and five doses of GNRs and GNSs. We did not observe any significant 
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differences in the accumulation profile of both particles. There was also no difference in 
the image contrast (due to nanoparticle labeling) provided by shells and rods. 
 
 
Figure 4.5. Composite NBI images of (a) and (b) single and five doses of nanorods (c) and (d) 
single and five doses of gold nanoshell solutions. The yellow arrows aindicate GNPs present in 
the tumor.  
 
4.4.5 Histopathology of liver, spleen and tumor for multiple doses 
We observed no signs of acute toxicity such as sinusoidal dilation, inflammation or 
necrosis in the tumor, liver and spleen for multiple doses. Figures 4.6a, b and c show light 
microscopy images of tumor, liver and spleen stained with H&E, respectively. 
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Figure 4.6: Light microscopy images of H&E stained tumor, liver and spleen from mice that 
received five doses of GNRs and GNR and a dose of trehalose (control).  
 
The extent of typical inflammatory cell infiltration (lymphocytes and neutrophils) was 
similar in Group 1 tumors (single dose of GNSs and GNRs), Group 3 (five doses of 
GNSs and GNRs) and the control group (dose of trehalose). In addition, there was no 
appreciable difference in edema (secondary to peritumoral inflammation) between tumors 
of previously mentioned groups. In addition, there were no significant differences in 
histopathological appearance observed in the livers (Fig. 4.6b) and spleens (Fig. 4.6c) 
between the groups. Furthermore, in tumors, livers and spleens analyzed, there was no 
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histopathologically appreciable necrosis as a result of any presumed increase in 
microvascular blockade by aggregated GNPs, even in the group that received multiple 
doses of GNPs. 
 
4.5 Discussion  
In this study, we have shown that multiple dosing of gold nanoparticles injected 
systemically leads to a cumulative increase in particle accumulation in tumors using 
NAA. Multiple dosing is a common approach used in photodynamic, chemo and 
radiation therapies to treat tumors. In addition, multiple dosing has been shown to 
protract tumor growth in mouse models. In a recent study, mice bearing subcutaneous 
Neuro2A tumors were treated by intravenous injection with siRNA-containing 
nanoparticles formed with cyclodextrin-containing polycations (CDP). Three consecutive 
daily doses of transferrin (Tf)-targeted nanoparticles carrying two different siRNA 
sequences targeting ribonucleotide reductase subunit M2 (RRM2) lead to slow tumor 
growth.89 The nanoparticles used in our present study are known to be effective in vivo 
tumor targeting agents.11, 88 In addition, their strong NIR plasmon peak (Figure 4.1) 
enables them to scatter, absorb or luminesce when excited in the NIR.90, 91  
Smaller particles have high permeation/diffusion through tumor interstitium and 
correspondingly, higher clearance to surrounding normal tissue (where they are likely to 
be cleared).92 Jain et al. and Boucher et al. have shown that the interstitial fluid pressure 
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decreases from the tumor core to the periphery and surrounding tissue, carrying 
nanoparticles with it by convection into the normal tissue as a function of particle size. 93, 
94 This phenomenon could explain the decrease in smaller nanoparticle accumulation in 
tumors with days as noted in Figure 4.2c (decreasing trend in GNR number density 
observed in tumors from three to five doses). In contrast, larger particles have restricted 
and slow migration to the tumor environment along with slow clearance from tumor 
owing to increased tumor accumulation with time.86, 94 This explains the increase in GNS 
number density with increasing doses (more time to accumulate slowly) as seen in Figure 
4.2a. However, a detailed study of the changes in nanoparticle accumulation in tumor for 
an extended time post single versus multiple dose delivery will help understand the 
mechanisms of uptake and clearance for various nanoparticle types.   
 We analyzed the livers of mice that received single and multiple dosing of both 
GNPs since liver has been shown to contain significantly higher nanoparticle 
accumulation compared to other RES organs.79 The statistically significant increase in 
tumor accumulation of GNPs with increasing dose number in the liver (Figure 4.2b) 
validates the multiple dosing approaches. However, we noticed an interesting trend in the 
GNR group. There was a drop-off in GNR accumulation from the three-dose group to the 
five-dose group (Figure 4.2d). Although uptake of particles from blood to liver may 
occur relatively quickly, excretion of these particles from the liver is relatively slow, 
often resulting in prolonged retention of GNPs.95 The decrease in GNR number density in 
the liver for the five-dose group, albeit statistically insignificant, is intriguing and 
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warrants further investigation.  
 Nanoparticles’ size and half-life plays an important role in tumor accumulation of 
particles for diagnostic and therapeutic purposes. Perrault et al. have shown that 
accumulation of smaller particles (less than 40 nm) in tumors is a function of both size 
and half-life. For particles larger than 40 nm, the accumulation is primarily a function of 
half-life.86 We used GNRs with a size of 24 x 7 nm having an approximate half-life 
between 4-8 hr and GNSs of 135 nm diameter with an approximate half-life of 3 hrs.67, 88 
The longer half-life and smaller size of GNRs explains their nearly 12-fold higher 
accumulation compared to the larger GNS.  
 With both particle types examined in this study, the highest tumor accumulation as 
a fraction of GNPs injected was only about 2%. Hobbs et al. have demonstrated that the 
vascular permeability and effective interstitial diffusion coefficient of a nanoparticle 
depends on the tumor type as well.96 The relatively low accumulation fraction of both 
pegylated GNRs and GNSs could be attributed to the tumor type as well. Pore cut-off 
sizes have been measured for a limited number of tumor models with the smallest 
reported at 100-200 nm.96 To our knowledge, the pore cut-off size for the squamous cell 
carcinoma tumors (A431 tumors) used in this study has not yet been reported. The size of 
the GNPs did not affect the accumulation in livers as observed in Figure 4.3b. This 
correlates well with prior research showing that nanoparticle accumulation in liver was 
irrespective of its size.79 However, as noted in an earlier paragraph, the GNRs appear to 
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clear much faster from the liver after three days.  
Although we noticed the effect of nanoparticle dosing strategy in tumor targeting 
and accumulation demonstrated using NAA, there was no effect in increase of image 
contrast observed through NBI (Figures 4.5). However, wide field NBI of the A431 
tumors demonstrated that nanoparticles accumulated in close proximity to blood vessels. 
This finding has been shown previously in several other studies46 and our diagnostic 
imaging tool confirmed the same.  In order to use NBI combined with increased GNPs’ 
contrast for tumor and tumor margin imaging, we intend to investigate other nanoparticle 
targeting strategies such as active targeting and nanoparticle delivery strategies such as 
topical delivery to effectively label and target the tumors. 
 The multiple dosing strategy did not lead to acute toxicity in mice during the 
course of the study. After administration of GNPs, mice were monitored daily for 
survival and behavior changes. There was no effect of fractioned dose administrations of 
GNPs on mortality and behavioral impairment. There were no appreciable 
histopathological signs of acute toxicity such as inflammation, edema, sinusoidal dilation 
and necrosis in all mice groups. Further studies are required to ascertain the effect of 
multiple dosing on long-term clearance, safety and biodistribution. Multiple dosing could 
potentially improve thermal therapy efficacy as the number densities accumulated in the 













Squamous cell carcinoma (SCC) is the second-most common skin cancer after 
basal cell carcinoma (BCC) with over 250,000 new cases detected every year.97 
However, SCCs are more likely to be aggressive and invade the dermal skin layers. 
Recently, several optical imaging techniques have been developed to enable rapid 
detection of non-melanoma skin cancers noninvasively in surgical skin excisions. The 
techniques include multispectral fluorescence polarization,98, 99 confocal reflectance 
microscopy,18, 100, 101 optical coherence tomography102, 103 and fluorescence 
spectroscopy.104 Several of these imaging methods have utilized extrinsic contrast agents 
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such as acetic acid, methylene blue and toluidine blue dyes to enhance contrast of the 
SCC tumor relative to the surrounding normal tissue. 
NIR-absorbing GNRs have considerable advantages over molecular dyes and 
fluorophores as contrast agents for NIR imaging applications. GNRs have tunable optical 
properties and high optical absorption cross sections in the NIR region, making them 
attractive probes for in vitro and in vivo imaging.38, 105 As described in previous chapters, 
nanoparticles when injected systemically or intravascularly, extravasate from the leaky 
neovasculature and accumulate in tumors due to the EPR effect. In an effort to increase 
targeting contrast, recent efforts have focused on active targeting strategies, wherein the 
nanoparticles’ surface is functionalized with antibodies to specifically target tumors.42-44 
Loo et al. demonstrated active targeting using anti-HER2 conjugated gold nanoshells to 
image breast carcinoma cells.106 El Sayed et al. have demonstrated active targeting of 
both nanospheres and nanorods using anti-EGFR antibodies in vitro. 53, 54 However, even 
with the systemic delivery of these particles, only a small percentage (~2%) of the 
administered nanoparticles reach the tumor target 67, and the residual material may raise 
concerns for toxicity and inadequate clearance from the body.  
To improve the percentage of nanoparticles delivered to tumors and reduce the 
quantity accumulating in vital organs, we topically applied antibody conjugated GNRs on 
tumor xenograft models and imaged using NBI. Recently, several research groups have 
used this delivery technique to specifically target disease tissues. Nitin et al. evaluated 
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the fluorescence contrast properties following topical delivery of 2-[N-(7-nitrobenz-2-
oxa-1,3-diazol-4-yl) amino]-2-deoxy-glucose (2-NBDG) in freshly resected clinical 
specimens of neoplastic oral mucosa using fluorescence imaging. 107 Bickford et al. used 
gold nanoshells as rapid diagnostic agents for imaging human breast tissue sections that 
over-expressed HER2 receptors. 65, 108 
We targeted the epidermal growth factor receptor (EGFR) over-expressed in 
SCCs (A431 cancer cells) using GNRs conjugated to Cetuximab (C225, a humanized 
anti-EGFR antibody that is currently approved for clinical use). EGFR is a 
transmembrane receptor tyrosine kinase stimulated by growth factors, such as 
transforming growth factor (TGF)-α or EGF, that binds to the extracellular domain of the 
receptor.109 EGFR promotes multiple tumorigenic processes, stimulating proliferation, 
angiogenesis and metastasis as well as protecting cells from apoptosis.110 EGFR is a 
viable molecular target that has been shown to highly over-express in several skin 
SCCs.111, 112 Several groups have used EGFR as probes to target, image and treat A431 
cells and tumor xenografts. Durr et al. used anti-EGFR antibody conjugated nanorods to 
detect and image A431 skin cancer cells embedded in a three-dimensional tissue scaffold 
using two-photon luminescence (TPL) microscopy.113 Recently, Melancon et al. used 
anti-EGFR antibody conjugated hollow gold nanoshells to target A431 cells in vitro and 
in vivo and performed photo-thermal ablation of cells in vitro.114  
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In this chapter, we present the results of a study exploring the feasibility of topical 
administration of anti-EGFR antibody conjugated GNRs (C225-GNRs) on A431 tumor 
cross-sections to target EGFR. We imaged tumor cross-sections topically administered 
with both C225-GNRs and pegylated GNRs (control) using NBI. We show that C225-
GNRs provided significantly higher tumor contrast compared to non-targeted pegylated 
GNRs (PEG-GNRs). In addition, we determined the penetration depth of the topically 
administered C225-GNRs and confirmed their binding affinity in tumors using two-
photon microscopy (TPM).  
 
5.2 Materials and Methods 
5.2.1 Bioconjugation of GNRs to Cetuximab (C225-GNRs) 
The synthesis of pegylated GNRs was carried according to the method of Jana et al. and 
has been described in Chapter 3. We adopted a three-step process for the bioconjugation 
of GNRs to Cetuximab. Our synthesis protocol utilizes the classical thiol-maleimide 
chemistry and the details of the conjugation process are as follows:  
Step-1: Functionalization of GNRs with PEG: Prior to conjugation the CTAB 
coated GNRs were briefly sonicated to disperse the GNRs in to a homogenous 
suspension. Methoxy-PEG-thiol (monofunctional PEG; mPEG-SH2K) and PEG bis Thiol 
(bifunctional PEG; SH-PEG5K-SH) were mixed in the ratio of 4:1 to arrive at a final 
concentration of 2mM. The freshly made PEG solution was mixed with clean GNRs in 
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the ratio of 1:9, stirred thoroughly and incubated for 1-2 hrs at room temperature, with 
gentle shaking. At the end of the incubation time the GNRs were centrifuged at 10,000 
rpm for 20 minutes to remove the unreacted PEG and the pellets were resuspended in 
PBS to form a uniform suspension of PEG-GNRs, with the terminal thiol (-SH) group at 
one end of the bifunctional PEG available for further conjugation with anitbody.  
Step-2: Activation of antibody: Cetuximab® (152 kDa), an anti-epidermal growth 
factor receptor (EGFR) antibody, is activated by reacting with a heterobifunctional 
crosslinker, succinimidyl 4-[N-maleimidomethyl] cyclohexane-1-carboxylate (SMCC; 
MW 334.32; arm length 0.83 nm) to expose the maleimide groups for the subsequent 
conjugation with PEG-GNRs containing free thiol (-SH) moieties. Approximately 20-fold 
molar excess of SMCC was added to the antibody solution (2mg/ml) and incubated for 2 
hrs at 4 °C. At the end of the reaction, the unbound cross linker molecules were removed 
by eluting the reaction mixture through a desalting column and the purified maleimide-
activated Cetuximab was collected in a clean tube for further reaction with PEG-GNR.  
Step-3: Conjugation of Cetuximab® to GNRs: The maleimide-activated 
Cetuximab (prepared from Step-2) was mixed with the PEG-GNRs with free thiol 
moieties (prepared from Step-1) such that the final concentration of maleimide-activated 
Cetuximab is ~ 10 µg/ml. After overnight reaction at 4 °C, the unbound antibody was 
removed by centrifugation at 10,000 rpm for 20 minutes.  The centrifugation step was 
repeated three times and the pellets were collected and reconstituted in sterile phosphate 
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buffered solution (PBS). The optical density of both PEG-GNRs (plasmon resonance 
peak @ 776 nm) and C225-GNRs (plasmon resonance peak @ 754 nm) was measured 
using UV-Vis spectrophotometer (Beckman Coulter DU720, Brea, CA) and their 
normalized extinction spectra are shown in Figure 5.1. 
 
 
Figure 5.1: UV-VIS extinction spectrum of PEG-GNRs and C225-GNRs. 
 
The conjugation efficiency was evaluated by measuring the zeta (ζ) potential of 
the final conjugates.  The CTAB coated GNRs used at the beginning of the conjugation 
process showed a zeta potential in the range +60 to +80 mV.  After the functionalization 
of GNRs with SH-PEG the zeta potential decreased to +5 to +10 mV.  With the addition 
of Cetuximab® to GNRs, the zeta potential further decreased and reached near neutral 
values in the range of +4 to -5 mV.  These values were consistent among different 
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conjugation batches indicating the efficiency of surface functionalization and 
Cetuximab® conjugation to the surface of GNRs.  Finally the conjugation efficiency was 
validated using protein assay by quantifying the ratio of Cetuximab® to GNR. Prior to the 
protein estimation the optical density (OD) of PEG-GNRs and C225-GNRs at the assay 
readout wavelength was adjusted to the same value.  PEG-GNRs and C225-GNRs were 
subjected to assay protocol and the assay end product was measured. With the known 
values of GNR/ml (2x1011 GNR/ml at 1 OD) and the measured concentration of C225 in 
the C225-GNR samples, the ratio of C225 molecules per GNR was estimated as ~110 - 
140 C225 molecules/GNR. 
 
5.2.3 Ex vivo mouse skin tumor tissues 
A431 cells (CRL- 1555, ATCC, human epithelial carcinoma cell line) were grown in 
Dulbecco's Modified Eagle's medium (30-2002, ATCC) with 10 % fetal bovine serum 
(30-2020, ATCC) at 37 °C under 5 % CO2. When culture reached 90 % confluency, the 
cells were detached from the flask by 0.25 % trypsin-EDTA (30-2101, ATCC), 
centrifuged, and re-suspended in sterile phosphate-buffered saline (PBS). Approximately 
4 x 106 cells/50 µl were subcutaneously injected in the right thigh of 4 to 5 week old 
nude mice (Swiss nu/nu). When tumors attained a size of ~ 8-10 mm in diameter, we 







5.2.4 Topical delivery of PEG-GNRs and C225-GNRs  
We performed topical delivery of both PEG-GNRs and C225-GNRs on A431 tumor 
cross-sections. The tumor sections were divided into the following two groups: 1) Group 
1 tumor cross-sections (n=6) received a topical delivery of 60 µl of PEG-GNRs and was 
designated the control group; 2) Group 2 tumor cross-sections (n=6) received 60 µl of 
C225-GNRs. The optical density of PEG-GNR solution was matched to that of C225-
GNR (OD = 25) by diluting in PBS before topically applying on tumors. Because PEG-
GNRs have no targeting moiety, they are treated as the control group in our experiments. 
Prior to nanoparticle delivery baseline NBI images were acquired.  Following baseline 
imaging, the tumor cross-sections were incubated with PEG-GNRs or C225-GNRs for 30 
minutes at 37 °C under 5 % CO2. At the end of incubation time, the tissues were washed 
three times with 1X PBS for NBI and two-photon microscopy. 
  
5.2.5 Two-photon microscopy   
We performed two-photon microscopy of the tumor samples incubated with C225-GNRs 
and PEG-GNRs using a custom-built NIR laser scanning multiphoton microscope 
described previously 115. Briefly, we used a femtosecond Ti: Sapphire laser (Mira 900 
with excitation wavelength of 800 nm; Coherent, Inc., Santa Clara, CA) as the excitation 
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source, and the laser beam was raster scanned along the sample using a pair of 
galvanometric scanning mirrors (6215HB; Cambridge Technology, Inc., Lexington, MA) 
to produce 2D images. We detected the two-photon luminescence from the GNRs using 
two photomultiplier tubes (PMT) (H7422P- 40, H7422P-50; Hammamtsu Corporation, 
Bridgewater, NJ) through a dichroic beam splitter (FF735-Di01; Semrock, Inc., 
Rochester, NY). We applied an incident laser power of 40.8 mW and band pass filtering 
of 6 dB gain. In order to determine the penetration depth of the GNRs, we obtained 
images (512 x 512 pixels) in the z-direction and created a stack of images to analyze the 
particle penetration as a function of depth. 
 
5.3 Results 
5.3.1 NBI of A431 tumors topically administered with PEG-GNRs  
Figure 5.2 presents a qualitative assessment of tumor cross-sections incubated with the 
control PEG-GNRs. The images show no perceivable contrast in the NIR using NBI. The 
red color in the NBI images corresponds to blood. We did not observe any PEG-GNRs in 




Figure 5.2: Images of EGFR over-expressing A431 tumor cross-sections captured before and 
after the incubation of PEG-GNRs. (a, b, and c) VIS, NIR and overlaid NBI images of A431 
tumors before incubation with PEG-GNRs, respectively. (d) Corresponding standard color image 
of tumor cross-section. (e, f and g) VIS, NIR and composite narrow-band imaging images of 
A431 tumors incubated with PEG-GNRs for 30 min. at 37°C, respectively. (h) Corresponding 
standard color image of tumor cross-section incubated with PEG-GNRs. The red color in the NBI 
images corresponds to blood. 
 
 
5.3.2 NBI of A431 tumors topically administered with C225-GNRs 
Figure 5.3 demonstrates that tumors incubated with GNRs targeted specifically to tumor 
growth factor receptors (bottom row) resulted in a significantly higher image contrast 
compared to the untargeted tumor (top row) as shown in Figure 5.3.  
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Figure 5.3: Images of EGFR over-expressing A431 tumor cross-sections incubated with and 
without C225-GNRs. (a, b, and c) VIS, NIR and overlaid NBI images of A431 tumors before 
incubation with C225-GNRs, respectively. (d) Corresponding standard color image of tumor 
cross-section. (e, f and g) VIS, NIR and composite NBI images of A431 tumors incubated with 
C225-GNRs for 30 min. at 37°C, respectively. (h) Corresponding standard color image of tumor 
cross-section incubated with C225-GNRs. The red color in the NBI images corresponds to blood 
and the green color corresponds to C225-GNRs attached to EGFRs expressed on A431 tumors. 
 
The red color in the NBI images corresponds to blood and the green color 
corresponds to EGFR-targeted GNRs attached to EGFRs expressed on A431 tumors. The 
composite NBI images of tumors demonstrated that GNRs targeted specifically to tumor 
growth factors resulted in higher nanorod binding to tumor receptors and a significantly 
higher image contrast compared to non-targeted gold nanorods (PEG-GNR). In addition, 
the NBI images highlight the regions of C225-GNR binding to the tumor receptors 
compared to the standard color images (Fig 5.4). 
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Figure 5.4: Images of EGFR over-expressing A431 tumor cross-sections incubated with PEG-
GNRs and C225-GNR for 30 min. at 37°C. (a and b) Standard color images of A431 tumor cross-
sections incubated with PEG-GNR and C225-GNR, respectively. (c and d) Corresponding 
composite near-infrared NBI images of A431 tumor cross-sections incubated with PEG-GNRs 
and C225-GNRs, respectively. The red color in the composite NBI images corresponds to blood 
and the green color corresponds to C225-GNRs attached to EGFRs expressed on A431 tumors. 
 
 
5.3.3 Quantitative analysis of tumor cross sections incubated with GNRs 
We quantified the image contrast obtained with tumor images from both experimental 
groups. Prior to topical application of GNRs, there was no significant difference in mean 
reflectance intensity between C225- and PEG-GNR treated tumors. As seen in the images 
from Figure 5.2, a topical application of PEG-GNRs did not lead to an improvement in 
image contrast; the mean reflectance intensity was nearly the same as the baseline 
measure. However, the mean reflectance intensity from tumors treated with C225-GNR 
 69 
was approximately 2.5 times higher than the reflectance from tumors treated with PEG-
GNRs (p < 0.05) as shown in Figure 5.5.  
 
 
Figure 5.5: Mean intensity values for samples of A431 tumors incubated with PEG-GNRs and 
C225-GNRs. Differences between EGFR over-expressing tumor incubated with PEG conjugated 
GNRs and EGFR-targeted GNRs was statistically significant (P < 0.05, n = 6). Differences 
between the post and pre C225-GNR delivery and incubation was statistically significant (P < 
0.05, n = 6). Error bars represent standard deviations. 
 
 
5.3.4 Two-photon imaging demonstrating EGFR binding of C225-GNRs 
We performed two-photon microscopy of the tumor samples incubated with both PEG-
GNR and C225-GNR to microscopically demonstrate the binding of EGFR targeted GNR 
in tumors and to study their depth profile. Figures 5.6a and b represent cross-sectional 
view of z-projected images of PEG-GNRs and C225-GNRs incubated tumors, 
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respectively. Panels c – f represent en-face two-photon images of PEG-GNRs and C225-
GNRs-incubated tumors obtained at different depths. C225-GNRs were mostly observed 
at depths of up to 300 µm from the tumor surface as seen in Figure 5.6b. On the other 
hand, we observed only traces of PEG-GNRs in the control image. A large proportion of 
signal in the control image can be attributed to instrument noise. This background signal 
is also visible in the C225-GNR image (Panel f) at 300 µm. The two-photon images of 
targeted GNR confirmed the specificity of C225-GNRs and their binding affinity to the 






Figure 5.6: (a, b) Cross-sectional view of z-projected images of PEG-GNRs and C225-GNRs 
incubated tumors. (c – f) en-face two-photon images of PEG-GNRs and C225-GNRs 
accumulated tumors obtained at different depths. C225-GNRs were observed to have maximum 
accumulation at a depth greater than 100 µm below the tumor surface. Figures 5.6a and b are on 
the same scale. 
 
5.4 Discussion 
In this study, we have shown that anti-EGFR antibody conjugated GNRs combined with 
near-infrared NBI could yield significant contrast for optical imaging of squamous cell 
carcinoma tumors. We used GNRs conjugated to antibody Cetuximab® (C225) for 
targeting EGFRs over-expressed in SCC tumors. The antibody conjugation on the GNRs 
resulted in a 22 nm blue shift in the extinction maximum as seen in Fig 5.1. The shift in 
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the plasmon resonance peak is possibly due to the change in the local refractive index 
resulting from antibody conjugation 116. However, the plasmon peak shift did not hinder 
imaging of both PEG-GNRs and C225-GNRs due to the optimum bandwidth of the NIR 
band pass filter utilized.  
Topically delivered anti-EGFR antibody conjugated GNRs provided enhanced 
visualization of A431 tumors using NIR NBI. The topical delivery method is a non-
invasive approach and can potentially reduce the interaction of particles with untargeted 
tissues. We have shown that GNRs targeted to EGFR significantly highlight the tumor 
tissue in the near-infrared NBI image (Fig 5.4f) compared to the NBI images of 
untargeted PEG-GNRs (Fig 5.3f). We observed that a small quantity (60 µl) of C225-
GNR delivered topically, is sufficient to produce substantial contrast in the images, 
suggesting that this delivery technique can reduce the amount of nanoparticles required 
for imaging applications. Recently, Aaron et al. demonstrated molecular binding of 
topically delivered anti-EGFR gold conjugates on human cervical biopsies and imaged 
EGFR using reflectance confocal microscopy.117 Bickford et al. have shown that 
topically administrated targeted gold nanoshells could help detect HER-2 over-expressing 
cells in human breast tissue sections using reflectance confocal microscopy.108 In 
addition, Nitin et al. evaluated the optical contrast achieved after topical delivery of EGF-
Alexa 647 that targeted EGFR in oral lesions using wide-field fluorescence imaging. 107 
To our knowledge, we show the first absorption based wide field optical imaging of anti-
EGFR antibody conjugated GNRs targeted to EGFR in SCC tumors. We could 
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potentially combine the effectiveness of the topical delivery method with wide-field NBI 
to aid in tumor and tumor margin detection during Mohs surgery. 
The near-infrared and composite NBI images of tumors incubated with C225-
GNRs demonstrated enhanced contrast of the tumors due to the binding of C225 to the 
EGF receptors. In addition, the comparison of color images and composite NBI images in 
Fig 5.5 demonstrated the utility of NIR NBI for better visualization of targeted tumors. 
We have used gold nanoparticles as contrast agent because they produce localized 
heating and could cause destruction of cancer cells when irradiated by a NIR laser at their 
plasmon peak.57 The NBI platform combined with targeted gold nanorods could 
potentially guide precise photo-thermal therapy without causing damage to surrounding 
normal tissue. Although we have used NIR absorbing GNRs for imaging the SCC 
tumors, one could also use NIR fluorophores targeted to EGFR and image using the NBI 
technique. 
Using two-photon microscopy, we evaluated the surface labeling as well as the 
potential penetration depth of the EGFR-targeted nanorods. Recently, two-photon 
microscopy has been used to demonstrate effective binding of anti-EGFR GNRs in A431 
cells 113 and anti-HER2 gold nanoshells in breast cancer cells. 65 The two-photon images 
of PEG-GNRs in Figs. 5.7 a, c-f (left columns) demonstrated that there is minimal effect 
of passive targeting (diffusion-mediated transport). We observed C225-GNRs at depths 
greater than 100 µm in the tumors. We believe this large penetration depth could be the 
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result of the long incubation time used in the study.  Due to the excellent levels of EGF 
binding at the current incubation times, we plan to determine the shortest incubation time 
that can still provide good image contrast.  
 Our results suggest that EGFR could be used as a molecular marker for the 
assessment of SCC tumors and potentially its margins. Therefore, it is important to 
understand the distribution of EGF receptors throughout the tumor tissue. We observed a 
homogenous distribution of the conjugated nanorods on the tumors due to the topical 
delivery approach. The tumor microenvironment has vascular abnormalities and poor 
lymphatics leading to high interstitial fluid pressure. 118 This interstitial hypertension 
restricts nanoparticle penetration into the tumor core when injected systemically, leading 
to a heterogeneous distribution in the tumor periphery.72 However, we believe that the 
topical delivery approach could help achieve a uniform nanoparticle distribution in 
tumors. The homogenous distribution of GNRs suggests that this accumulation profile 




















This chapter presents ongoing work using the second-generation NIR NBI system. The 
real-time system developed in Chapter 4 is used in ex vivo and in vivo settings to identify 
tumor margins. This chapter represents a culmination of our efforts towards building a 
portable, clinically compatible, real-time system for imaging tumor margins by exploiting 
exogenous contrast from nanoparticles. We also present an additional component that can 
help perform photo thermal therapy on the tumors. We have performed our studies on 
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two cancer models that best represent the urgent need for a real-time intraoperative 
surgical guidance tool – breast and pancreatic cancer.  
 
6.2 Introduction 
Most breast cancer patients have surgery to remove the tumor from the breast. The main 
purpose of breast conservation surgery is to remove the entire tumor and obtain clear 
margins around the cavity to decrease the chance of local tumor recurrence.  However 
there are challenges identifying the residual tumor at the margin. Therefore, techniques 
that aid in identifying positive surgical margins intraoperatively may have a significant 
impact on survival and disease progression. 
  For all stages of pancreatic cancer combined, the 5-year survival rate remains at a 
low 5%, making it the most lethal of all solid tumors.119 Only about 10% of patients are 
presented with resectable disease and are suitable for potentially curative surgery.120 Even 
for patients who are qualified for surgery, aggressive metastasis often occurs after the 
operation since there are technical challenges identifying the resection margin status 
during surgery. 
In this chapter, we present preliminary experiments conducted to determine 
feasibility of ex vivo and in vivo imaging of a breast tumor model that received both 
systemic and topical delivery of PEG-GNRs and antibody conjugated GNRs. We also 
present initial feasibility to evaluate the efficacy of real-time NBI combined with photo 
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thermal ablation to treat positive pancreatic tumor margins in a small cohort of mice. We 
performed ex vivo and in vivo NIR NBI of the pancreatic tumor margins accumulated 
with systemically injected pegylated and conjugated GNSs.  
 
6.2 Materials and methods:  
The imaging and photo thermal ablation of tumors were carried out at Nanospectra 
Biosciences Inc. and MD Anderson Cancer Center in Houston, TX. 
 
6.2.1 MCF-7 breast cancer line 
We used female Fox 1nu mice inoculated in the mammary fat pad and flank with breast 
cancer cells (MCF-7).  Tumors sizes were measured regularly and reached ranges 
between 3 – 5 mm over 3 months. The mouse received 4.5µL/g of GNR solution 
normalized to an optical density of 52 at 800nm injected intravenously via the tail vein.  
The mouse was sacrificed 24hr following GNR injection, and the bulk tissue containing 
the tumor was resected from the mouse. We imaged 3 flank tumors and 2 mammary fat 
pad tumors from a total of four mice (n=4) using NIR NBI. 
For in vivo imaging, we brought the NBI system from UT Austin to Nanospectra 
Biosciences facility. We performed in vivo narrow band imaging of MCF-7 breast tumors 
that received systemic injections (n=3) and topical administration (n=3) of PEG-GNRs 
and folic acid conjugated GNRs. The mice were anesthetized using the approved 
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ketamine/xylazine/acepromazine cocktail. An incision was made in the skin of the flank, 
exposing the subcutaneous tumor and cross-section for imaging.  
For topical delivery, we administered 200 µL of the conjugated nanorod 
suspension (optical density = 5) with plasmon resonance peak at 772 nm.  After 30 
minutes, we washed the tumor cross-sections and surrounding tissue thrice with 1X PBS. 
The tumor cross-sections along with the surrounding normal tissue were imaged in vivo 
using NBI.  
 
6.2.2 MiaPaCa- 2 pancreatic tumor model 
The animal model was developed at the MD Anderson Cancer Center research facility at 
Houston. Luciferase transfected MIAPaCa-2 cells were subcutaneously injected in the 
right flank of nude mice. Once the required tumor size (8-10 mm) was reached, GNSs 
were systemically injected. After 24 hrs, the mice were anesthesized and received 
luciferin (150 mg/kg i.p) 10 min prior to imaging. Ten minutes after luciferin injection, 
bioluminescence was measured using the IVIS imaging system (Xenogen corporation, 
US) to detect viable cancer cells. An incision was made on the skin overlying the tumor 
to expose the tumor. The exposed tumor was resected leaving positive margins or 
residuals. The surgical bed with positive margins was re-imaged using both 
bioluminescence imaging and NBI.  
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6.2.3 Evaluation of ex vivo and in vivo NIR NBI of pancreatic tumor margins  
A pancreatic cancer xenograft model of minimal residual disease (MRD) was established 
to perform NIR NBI. In collaboration with researchers at MD Anderson Cancer Center, 
we established an animal model with MRD to mimic positive resection margins of 
pancreatic cancer. This model represented residual disease after surgery and/or 
inoperable pancreatic cancer identified at the time of surgery. In general, surgeons 
remove as much tumor at the retroperitoneal margin as technically feasible. Any further 
resection is generally unsafe due to fear of denervating the bowel by injuring nerves 
running along the vessels along this margin.  
We used a small group of mice (n=6) to test the feasibility of the minimal residual 
disease model ex vivo. Animals were randomly distributed in three groups: a) control 
group (n=2), b) untargeted pegylated gold nanoshells injected (n=2), and c) RGD 
conjugated gold nanoshells injected mice (n=2). After 24 hrs following gold nanoparticle 
and trehalose delivery, the MRD was established followed by bioluminescence imaging. 
The mice were euthanized and the tumors excised for imaging. 
For in vivo imaging, eleven animals were randomly distributed in three groups: a) 
control group (n=5) (trehalose injected and laser treated), b) untargeted PEG-GNSs 
systemically injected and laser treated (n=2), and c) RGD conjugated gold nanoshells 
systemically injected and laser treated (n=4). After 24 hrs following gold nanoparticle 
and trehalose delivery, the mice were anesthetized using the approved 
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ketamine/xylazine/acepromazine cocktail and the MRD was established followed by 
bioluminescence and NIR NBI.  
 
6.2.4 Combined NBI and thermal ablation setup  
We evaluated the initial feasibility to perform image-guided photothermal therapy of the 
residual tumors. We combined a laser with the second generation NBI system to perform 
image-guided surgery of pancreatic tumor margins. Laser irradiation was performed 
using a NIR diode laser for 3 min. (808 nm and 4 mW/cm2). The temperature increase 
was monitored using a temperature sensor. Figure 1 shows the combined system for in 
vivo image guided therapy of pancreatic tumor margins in a mouse model. 
 
 
Figure 6.1: Combined system for in vivo image guided therapy of pancreatic tumor margins in a 




6.3.1 Ex vivo imaging of gold nanorods in MCF-7 tumor 
Figure 6.2 shows representative images of the flank tumor imaged using NIR NBI. The 
images demonstrated the feasibility of imaging GNRs in MCF-7 tumors using NIR NBI. 
However, we observed GNRs only in only one out of three flank tumors.  
 
 
Figure 6.2. Ex vivo images of a MCF-7 flank tumor a) Narrow band VIS image assigned to red 
channel, b) Narrow band NIR image assigned to green channel, c) Composite NBI image, and d) 
Standard color image. 
 
6.3.2 In vivo imaging of gold nanorods in MCF-7 tumors 
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Figure 6.3 demonstrates in vivo imaging of MCF-7 tumor cross-sections accumulated 
with PEG-GNRs using NBI.  GNRs were not detected on the superficial tumor capsule of 
any of the three viewed tumors.  Therefore, we sliced each tumor transversely exposing 




Figure 6.3. (a) Narrow band grayscale VIS image, (b) Narrow band grayscale NIR image, (c) 
Standard color image, (d) Narrow band VIS image assigned to red channel, (e) Narrow band NIR 
image assigned to green channel, and (f) Composite NBI image. The yellow arrow indicates 
GNRs. 
 
6.3.3 In vivo NIR NBI imaging of folic acid conjugated gold nanorods topically 
administered on MCF-7 tumors 
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Figure 6.4 is a representative image of one of the three tumors that received topical 
delivery of folic acid conjugated GNRs imaged using NBI. Although the MCF-7 tumor 
line is known to express the folic Acid receptor, we did not observe nanorod labeling in 
the tumors after incubation for 30 minutes.   
 
 
Figure 6.4. MCF-7 tumors topically administered with folic acid conjugated gold nanorods.  
(a) Narrow band VIS image assigned to red channel (b) Narrow band NIR image assigned  
to green channel (c) Composite NBI image (d) Corresponding standard color image.  
 
6.3.4 Ex vivo imaging of pancreatic tumor margins 
Figure 6.5 is a representative image of a tumor accumulated with RGD conjugated GNSs 
and imaged using bioluminescence and NBI. We demonstrated the ability of the NIR 
narrowband system to detect the low levels of gold nanoshells that accumulated within 






Figure 6.5: Sensing and imaging resection margins using conjugated gold nanoshells. (a) 
Bioluminescence imaging of resection margins in a mouse with a resected xenograft of luciferase 
transfected MiaPaca cells. (b) In the same mouse, injection of RGD conjugated gold nanoshells 
shows presence of the particles in the tumor bed post-surgery using NIR narrowband imaging 
(red circles).  
 
6.3.5 In vivo image-guided therapy of pancreatic tumor margins 
Figure 6.6 represents in vivo NBI of pancreatic tumor margin. We observed minimal 
signal from the conjugated gold nanoshells present in the margin. Following detection of 
conjugated GNSs, we performed image guided thermal ablation using the setup described 
in section 6.2.4.  The laser ablation did not result in significant temperature increase to 
ablate the tumor cells and was confirmed using bioluminescence imaging.  
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Figure 6.6. (a) Narrow band grayscale VIS image, (b) Narrow band grayscale NIR image, (c) 
Standard color image, (d) Narrow band VIS image assigned to red channel, (e) Narrow band NIR 




In order to use the NIR NBI system for real-time tumor margin detection, we expected 
higher nanoparticle accumulations in the MCF-7 breast tumors.  Although we could 
identify the GNRs present in some tumors, the nanorod accumulation concentration 
observed was very minimal. MCF-7 tumors are known to express high levels of folate 
receptor.121 Therefore, we performed topically delivery of folic acid conjugated GNRs on 
the MCF-7 tumors. However, we did not observe any labeling following 30 minutes of 
incubation. Further analysis on the levels of folate receptor expression and specificity of 
the folic acid conjugated GNRs to these tumors are required.   
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The principal limitation in the breast tumor imaging study was the failure of the 
tumor/mouse model to yield rapidly growing breast tumors that would have provided a 
realistic proliferating vasculature for passively accumulated and topically delivered 
nanoparticles. We believe that Fox 1nu nude mouse may not be an optimal model due to 
its very slow growth rate (~2- 3 months) resulting in a small tumor (mostly 3 x 3 x 1 
mm). We have on-going work to identify a suitable breast tumor model and establish 
minimal residual disease for the same. The NBI system, however, demonstrated that it is 
robust (the system was transported and re-assembled for each of the imaging sessions), 
sensitive, and consistent. We anticipate that coupling the NIR NBI system with a 
successful in vivo model will provide pre-clinical, efficacy data that will justify its use in 
clinical settings. 
The NBI images showing pancreatic tumor margin contained very few conjugated 
gold nanoshells (Figure 6.5 and 6.6). Spurious signal was noted at the skin fold along the 
tumor margin that could be due to effects of shadowing and index mismatch.  However, 
good correspondence between bioluminescence and narrow-band imaging suggest that 
low levels of residual tumor are readily detectable using this technique.  
Image guided thermal ablation performed in the pancreatic tumor margins did not 
produce significant heating to ablate the tumor cells. This was mainly due to 
inappropriate laser power settings and laser probe positioning. In order to conduct 
effective thermal therapy in the future, we intend to perform and test laser ablation in ex 
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vivo models and determine the optimum settings required to ablate the cancer cells 








Conclusion and future directions 
 
7.1 Summary 
There is a clear need for technology which will increase the percentage of patients 
achieving a clear margin with surgery.  Therefore, any technology that could help a 
surgeon visualize the tumor at the margin intraoperatively would aid in achieving clear 
margins. This dissertation presents a novel imaging technique called near-infrared 
narrow-band imaging combined with gold nanoparticles as contrast agents to image 
tumor and its margins intraoperatively.  
In the second chapter, we present the prototype NIR NBI system and demonstrate 
that the system can effectively highlight GNSs systemically delivered to tumors. We 
illuminated the target using broadband light and collected narrow band of images in the 
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VIS and NIR to highlight absorption of hemoglobin and GNS in colon tumor xenografts. 
We quantitatively identified the narrow wavelength bands for imaging that provides 
enhanced visualization of both hemoglobin and GNSs in tumors. The preliminary results 
obtained from in vitro and ex vivo imaging were promising and also suggested that NIR 
NBI is a feasible technique to identify positive margins during surgical resection of 
tumors. The identification of tumor regions is a first step to image-guided surgical 
removal of tumor margins or photo thermal therapy. The NBI technique could potentially 
provide a platform for integrated cancer imaging and therapy. 
In Chapter 3, we discuss our efforts towards optimizing the prototype NIR NBI 
system to make it compact, portable as well as achieve real-time imaging capabilities. A 
filter wheel containing band pass filters was replaced with the LCTF to acquire two 
images; one in the visible and other in the near infrared portions of the spectrum to image 
the blood vessels and gold nanoparticles, respectively.  The real-time imaging capabilities 
were achieved by having an AC motor control the filter wheel rotation and timed to 
trigger an optical interrupt to enable imaging at the filters position. The original quartz-
halogen illumination system was replaced with visible and near infrared LED’s which 
lowered the power requirements and increased the discrimination in simultaneously 
illuminating blood vessels and nanoparticles. We developed a graphical user interface to 
display the images and provide controls to dynamically adjust the image features such as 
brightness and contrast of each channel. The depth of imaging sensitivity was measured 
using physiologically relevant nanoparticle concentrations embedded at various depths 
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within a tissue-mimicking phantom.  We did not observe loss of contrast until the 
nanoparticle concentration reached ~1.72 X 1011 particles/mL and a depth of 
approximately 2 mm, suggesting tumor visualization to that depth. 
  Chapter 4 investigates the effects of particle type, size and dosing on tumor 
targeting and accumulation for effective imaging and therapy. The results from NAA 
show that smaller particles have enhanced accumulation in tumors compared to larger 
nanoparticles. In addition, NAA data demonstrated that multiple nanoparticle dosing 
caused higher particle accumulation in tumors compared to a single dose. 
Histopathological analysis of the tissues confirmed no acute toxicity as an effect of 
multiple dosing. However, multiple dosing in mice did not contribute to increased NBI 
image contrast, which is considered a key to performing image-guided margin resection. 
In addition, we continued to observe heterogeneity in nanoparticle accumulation in 
tumors with multiple dosing that could affect effective photo-thermal tumor therapy. 
  In chapter 5, we utilized topically delivery approach to label the non-melanoma 
skin tumors using anti-EGFR antibody conjugated GNRs and imaged using NIR NBI. 
NBI demonstrated that the conjugated GNRs were effective probes for EGFR expression 
in squamous cell carcinomas. Using near-infrared NBI and two-photon microscopy, we 
demonstrated that anti-EGFR GNRs specifically bound to EGFRs over-expressed in 
A431 tumors and improved optical visualization of SCC tumors. The C225-GNRs 
attached to the over-expressed EGF receptors providing an enhanced intensity of up to 
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2.5 fold. Our data suggests that the combined use of targeted GNRs and near-infrared 
NBI may potentially aid in tumor margin assessment based on EGFR-expression levels 
serving as a valuable diagnostic tool during surgical resection of SCC tumors. 
  Finally, in chapter 6 we demonstrated the feasibility of using the real-time NBI 
system to image breast and pancreatic tumor margins intraoperatively. We also 
demonstrated feasibility of performing image-guided therapy of pancreatic tumor 
margins. In order to clinically translate the system to potentially perform NBI during 
surgery in humans, we need to execute further in vivo studies with a larger animal model, 
optimized laser parameters and suitable contrast agents. 
 
7.2 Future Work 
Our second-generation real-time narrow-band imaging system currently acquires and 
processes images at 6 fps. The existing system has proved the feasibility of performing 
intraoperative imaging of tumor and its margins. However, for clinical purposes, a faster 
image acquisition and processing is desirable. The rate-limiting step in the current system 
is the image processing that involves overlaying VIS and NIR grayscale images to obtain 
and display composite images. Therefore, integrating a graphics video card in the system 
could potentially increase the process. It will enable faster image processing/display and 
achieve imaging rates near the standard 30 fps (video-rate). Integrating a graphics video 
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card will potentially enable imaging 12 bit images eliminating the necessity to bin and 
therefore improve image resolution.  
Additionally, our current real-time system collects two narrow-band images (NIR 
and VIS) sequentially.  Motion artifacts due to the mouse’s rapid cardiac and respiratory 
activity make this approach problematic. To completely eliminate these motion artifacts, 
the two frames need to be collected simultaneously.  This could be accomplished by 
implementing a lens array system, which will acquire multiple narrow band images 
simultaneously through multiple independent imaging channels. Specifically, we will 
design and construct a multiaperture camera, based on a single CCD, using 2 (or more, as 
required) individual lenses, forming 2 separate sub images on a single CCD frame. In 
front of the 2 lenses we will mount a plate that will hold multiple individual optical 
elements such as band pass filters that alter the optical information in a single sub image. 
We believe that this approach will constitute an effective real-time imaging system, 
especially in conditions where motion artifacts are an issue. 
We studied the effect of multiple dosing on nanoparticle accumulation in tumors 
for GNRs and GNSs. It will be interesting to study multiple dosing for different particle 
sizes for the same particle type (e.g. GNRs of different aspect ratios or GNSs of different 
diameters) for a particular tumor model and study their effect on tumor accumulation 
patterns and biodistribution. In addition, it will be interesting to study the effect of 
multiple dosing for different dilutions of a given nanoparticle type and size. Although we 
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have shown the effect of multiple dosing using passive targeting of pegylated GNPs in 
chapter 3, it will be interesting to see the effect when the particles are actively targeted 
(antibody conjugated to target specific receptor).  
We demonstrated NBI of squamous cell carcinoma mouse tumors that received 
topical delivery of conjugated GNRs. The incubations times used in the study (30 
minutes) were based on the optimum and standard time considered for particles to be 
taken up by cells. However, in order to use this delivery approach combined with 
intraoperative imaging during Mohs surgery, a shorter labeling time would be desirable. 
Therefore, we will perform ex vivo studies on mouse tumors and human tumor sections to 
determine an optimum and shorter incubation time that provides good tumor image 
contrast with respect to surrounding tissue for intraoperative NBI. We will use the 
optimum time determined through ex vivo studies to evaluate NBI of topically delivered 
conjugated GNPs in human skin tissues. We will obtain the human skin tissues from a 
tissue bank to conduct this study and demonstrate the capability of NBI system to image 
human tumors.  
We tested the second-generation NBI system to perform in vivo tumor and tumor 
margin imaging in breast and pancreatic tumor models. We also attempted to perform 
image-guided thermal therapy. As a follow up to thermal therapy after optimizing the 
laser parameters, we will perform histology of the treated tumor samples to confirm 
ablation. Once the combined imaging and therapy is successful, we will perform 
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longitudinal tumor volume studies. We will perform longitudinal tumor volume studies to 
evaluate treatment outcome following image-guided therapy. The animal groups will be 
similar to section 6.2.3 (in vivo imaging animal group). Following photothermal therapy, 
animals in the sham-treatment and laser-treatment groups will undergo bioluminescence 
imaging. Subsequently, all animals will undergo bioluminescence-imaging twice weekly 
to check for local recurrence as well as metastasis.  We will euthanize the mice after 4 
weeks to measure tumor volume. We will perform statistical analysis to determine 
significant difference among the groups. If successful, we will perform a preclinical 
longitudinal tumor volume study to evaluate treatment outcomes following image-guided 
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